Document:

Exhibit 10.17

 

 

Cognition Therapeutics Inc.

2403 Sidney Street

Pittsburgh PA 15203

t: 412 481 2210 f: 412 481 2216

 

www.cogrx com

 

October 7, 2019

 

Mr. James O’Brien

20 Hollow Tree Ridge Road

Darien, Connecticut 06820

 

Dear Jim:

 

This letter agreement (the
 “Agreement”) sets forth the terms and conditions of your employment with Cognition Therapeutics, Inc., a Delaware corporation
(the “Company”).

 

1.            Position
and Duties.

 

(a)            Position.
Effective October 28, 2019 (the “Start Date”), you shall commence your employment with the Company as its Chief Financial
Officer. This Agreement will set forth the terms and conditions of your employment in such capacity.

 

(b)            Duties.
Your employment by the Company shall be full-time and exclusive of any other employment and you shall devote all of your business time,
attention and services to the Company and its Affiliates (as defined below). You will perform such duties as may be customary to, and
consistent with, the position of Chief Financial Officer, and such duties that may reasonably be assigned from time to time by the Chief
Executive Officer. You will devote your best efforts, business judgment, skill and knowledge to the advancement of the business and interests
of the Company and to the discharge of your duties and responsibilities to the Company. Notwithstanding the foregoing, during the term
of your employment, you may participate in charitable activities and manage your passive investments, in each case so long as such activities
do not interfere with the performance of your duties and responsibilities hereunder or present a conflict of interest with the Company
or its Affiliates.

 

(c)            Office
Location. You shall perform your services hereunder primarily at the Company’s offices to be established in the Tri-State (New
York, New Jersey, Connecticut) area, and in Pittsburgh, PA, subject to reasonable business travel.

 

2.            Compensation
and Benefits. During your employment, as compensation for all services performed by you for the Company, the Company will provide
you the following pay and benefits:

 

(a)            Base
Salary. The Company will pay you a base salary (the “Base Salary”) at the rate of $340,000 per year, payable in accordance
with the regular payroll practices of the Company and subject to adjustment from time to time by the Company’s Board of Directors
(the “Board”) in its discretion.

 

    

     

    

 

Mr. James OBrien

October 7, 2019

Page Two

 

(b)            Bonus
Compensation. During your employment, you will be considered annually for a cash bonus targeted at 30% of your Base Salary. The amount
of any bonus awarded to you for any year will be determined by the Board in its discretion, based on your performance and that of the
Company against the specific priorities and/or goals established for each such annual period by the Board. Any annual bonus will be paid
in the year following the fiscal year with respect to which such annual bonus was earned and attributable, at the same time as other executives
receive any applicable bonus compensation and as soon as practicable following the availability of the Company’s results of operations
for the applicable fiscal year. Subject to Section 5(a)(i), in order for you to receive payment of any such annual bonus, you must
be employed by the Company on the date of payment.

 

(c)            Stock
Options. In connection with the commencement of your employment, the Company’s management will recommend that the Board grant
you a stock option (the “Option”), under and subject in all respects to the Cognition Therapeutics 2017 Equity Incentive Plan
(the “Plan”) and award agreement, to purchase the number of shares of the Company’s common stock, par value $0.001 per
share (the “Common Stock”) equal to 0.75% of the Company’s outstanding equity on a fully diluted basis. The Option will:
(A) have an exercise price per share equal to the fair market value per share of Common Stock on the date of the grant, as determined
by the Board; and (B) will be subject to vesting requirements such that (i) 25% of the shares of Common Stock underlying the
Option shall vest as of the first anniversary of the Start Date, and (ii) the remaining 75% of the shares of Common Stock underlying
the Option shall vest in 36 substantially equal monthly installments as of the last day of each month thereafter, in each case if you
remain continuously employed by the Company through the applicable vesting dates; provided, however, that any then-unvested portion
of the Option shall vest upon the closing of a Change in Control (as defined in Section 6) if you remain employed through such event.

 

(d)            Participation
in Employee Benefit Plans. You shall be eligible to participate in any and all employee benefit plans from time to time in effect
for employees of the Company generally. The Company shall not be required to establish or maintain any such program or plan. Such participation
shall be subject to (i) the terms of the applicable plan documents, and (ii) generally applicable Company policies. The Company
may alter, modify, add to or terminate its employee benefit plans at any time as it, in its sole discretion, determines to be appropriate.

 

(e)            Paid
Time Off. You will be entitled to 4 weeks vacation, in addition to holidays observed by the Company, pursuant to the Company’s
paid-time-off policies. Vacation may be taken at such times and intervals as you shall determine, subject to the business needs of the
Company and prior notice to the Chief Executive Officer.

 

(f)            Business
Expenses. The Company will pay or reimburse you for all reasonable business expenses incurred or paid by you in the performance of
your duties and responsibilities for the Company, subject to any maximum annual limit and other restrictions on such expenses set forth
by the Company and to such reasonable substantiation and documentation as the Company may specify from time to time.

 

3.            Confidential
Information; Restricted Activities; Intellectual Property. To induce the Company to enter into this Agreement, as a condition to
your employment by the Company, and in recognition of (i) the compensation payable to you pursuant to this Agreement, and
(ii) such other consideration payable to you by the Company or any of its Affiliates, you must sign and return to the 

 

    

     

    

 

Mr. James OBrien

October 7, 2019

Page Three

 

Company
no later than your Start Date the Confidential Disclosure, Invention Assignment, Noncompetition, Non-Solicitation and
Non-Interference Agreement attached hereto as Exhibit A (the “Restrictive Covenants Agreement”).

 

4.            Termination
of Employment. Your employment under this Agreement shall continue for no definite term until terminated pursuant to this Section 4.

 

(a)            The
Company may terminate your employment for Cause upon notice to you setting forth in reasonable detail the nature of the Cause (as defined
below). The following, as determined by the Company in its reasonable judgment, shall constitute “Cause” for termination:
(i) your persistent and willful refusal to follow reasonable directives of the Chief Executive Officer; (ii) gross negligence
or willful misconduct in the performance of your duties and responsibilities to the Company or any of its Affiliates; (iii) your
material breach of this Agreement or any other agreement between you and the Company, which breach continues for more than 15 days after
the Company gives you written notice that sets forth in reasonable detail the nature of such breach; or (iv) other conduct by you
that is or could reasonably anticipated to be materially harmful to the business, interests or reputation of the Company or any of its
Affiliates. The Company may terminate your employment as a result of your Disability and at any time other than for Cause upon notice
to you. Termination of your employment as a result of your Disability will not be construed as a termination by the Company “other
than for Cause.”

 

(b)            You
may terminate your employment at any time upon 60 days’ notice to the Company without Good Reason. You may also terminate your employment
with Good Reason. “Good Reason” means, without your consent: (i) a material diminution by the Company of your responsibilities
with the position you then hold, or (ii) the Company reduces your Base Salary, other than in connection with the same percentage
across-the-board decrease in base salaries applicable to other key executives; provided that, in each case, written notice of your resignation
for Good Reason must be delivered to the Company within thirty (30) days after the occurrence of the event falling within the definition
of Good Reason in order for your resignation for Good Reason to be effective, the Company fails to cure such event within thirty (30)
days after delivery of such notice to cure any such event and you resign your employment within thirty (30) days following the expiration
of that cure period.

 

(c)            This
Agreement shall automatically terminate in the event of your death during employment.

 

5.            Severance
Payments and Other Matters Related to Termination.

 

(a)            Involuntary
Termination/Good Reason Termination.

 

 (i)            In
the event of termination of your employment by the Company other than for Cause, or your resignation of employment for Good Reason,
the Company (or its successor, as applicable) will (A) continue to pay you your Base Salary for a period of six (6) months
after the date of termination; (B) pay you for any bonus to which you would have otherwise been entitled for the prior fiscal
year but for the termination of your employment prior to payment of such bonus; and (C) waive the applicable premium otherwise
payable for COBRA continuation coverage for you (and, to the extent covered immediately prior to the date of such cessation, your
eligible dependents) for a period equal to six (6) months following termination; provided, however, that if such termination
occurs within eighteen (18)

 

    

     

    

 

Mr. James OBrien

October 7, 2019

Page Four

 

 months after your Start Date, the Base Salary continuation described in subsection (A), and the
subsidized COBRA coverage described in subject (C), shall be provided for nine (9) months in lieu of six (6) months. The
Company will also pay you any Base Salary earned but not paid through the date of termination, pay for any vacation time accrued but
not used to that date and reimburse any business expenses incurred in accordance with Company policy and subject to the
Company’s policies regarding appropriate documentation (the “Accrued Rights”).

 

 (ii)            Notwithstanding
the foregoing, in the event your employment is terminated by the Company (or its successor) other than for Cause or by you for Good Reason,
in each case during the twelve (12) month period immediately following the occurrence of a Change in Control (as defined below), you will
receive the payments and benefits described in Section 5(a)(i) above, subject to the following modifications: (A) references
in in Section 5(a)(i) to “six (6) months” or “nine (9) months” (as applicable) will each be
replaced with a reference to “twelve (12) months”; and (B) all unvested restricted stock, stock options and other equity
incentives awarded to you by the Company will become immediately and automatically fully vested and exercisable (as applicable). The payments
described in subsection (A) of this Section 5(a)(ii) shall be paid in a lump sum not later than the forty-fifty (45th)
day following your termination of employment.

 

(b)            Limitation
of Payments. If any payment or benefit due under this Agreement, together with all other payments and benefits you receive or are
entitled to receive from the Company or any of its Affiliates, would (if paid or provided) constitute an excess parachute payment (within
the meaning of Section 280G(b)(1) of the Code), the amounts otherwise payable and benefits otherwise due under this Agreement will
be limited to the minimum extent necessary to ensure that no portion thereof will fail to be tax-deductible to the Company by reason of
Section 280G of the Code or result in an excise tax pursuant to Section 4999 of the Code. The determination of whether any payment
or benefit would (if paid or provided) constitute an excess parachute payment will be made by the Board, in its sole discretion. If a
reduction to the payments otherwise payable under this Agreement or any other arrangement is required pursuant to this Section 5(b),
such reduction shall be made in the following order: (i) first, any future cash payments (if necessary, to zero); (ii) second,
any current cash payments (if necessary, to zero); (iii) third, all non-cash payments (other than equity’ or equity derivative
related payments) (if necessary, to zero); and (iv) fourth, all equity or equity derivative payments; provided that in all events,
such reductions shall be done in a manner consistent with the requirements of Section 409A of the Code, to the extent applicable.

 

(c)            Severance
Conditional upon Release. The payments and benefits described in Section 5(a) are in lieu of, and not in addition to,
any other severance arrangement maintained by the Company. Notwithstanding any provision of this Agreement, the payments described
in Section 5(a) (other than the Accrued Rights) are conditioned on your execution and delivery to the Company of a general
release of all claims against the Company and its Affiliates in a manner consistent with the requirements of the Older Workers
Benefit Protection Act and any other applicable law, and in a form reasonably prescribed by the Company (the “Release”)
and such Release becoming irrevocable within sixty (60) days following the date of termination and (ii) your continued
compliance with the Restrictive Covenants Agreement. The severance benefits described in Section 5(a) (other than the
Accrued Rights) will be paid or begin to be paid or provided within sixty (60) days following your date of termination; provided
that the initial payment of Base Salary continuation shall include a catch-up payment to cover amounts retroactive to the day
immediately following the effective date of your termination of employment. If the severance benefits payable pursuant to
Section 5(a) are deferred compensation subject to the requirements of Section 409A of 

 

    

     

    

 

Mr. James OBrien

October 7, 2019

Page Five

 

the Code, and if the 60-day
period described herein begins in one taxable year and ends in a second taxable year, such payments shall not commence until the
second taxable year.

 

(d)            Termination
for Cause, upon Disability, or by Voluntary Termination. In the event of termination of your employment by the Company for Cause or
Disability, or your voluntary termination of employment, the Company will pay you the Accrued Rights. The Company shall have no other
obligation to you, including any bonus or severance payments.

 

(e)            Survival
of Certain Provisions. Provisions of this Agreement shall survive any termination if so provided in this Agreement or if necessary
or desirable to accomplish the purposes of other surviving provisions. The obligation of the Company to make payments to you under this
Section 5, and your right to retain such payments, are expressly conditioned upon your continued full performance of your obligations
under the Restrictive Covenants Agreement. Upon termination by either you or the Company, all rights, duties and obligations of you and
the Company to each other shall cease, except as otherwise expressly provided in this Agreement.

 

6.            Definitions.
For purposes of this Agreement, the following definitions apply:

 

“Affiliate” means
any Person that controls, is controlled by or under common control of the Person, with “control” meaning the ownership or
right to vote at least a majority of the equity interests of such Person.

 

“Change in Control”
means (A) the sale, lease, exchange, transfer or other disposition of all or substantially all of the assets of the Company and its
Affiliates, or (B) any sale, merger, consolidation or other business combination that results in the holders of the outstanding voting
securities of the Company immediately prior to such transaction beneficially owning or controlling less than a majority of the voting
securities of the surviving entity immediately thereafter.

 

“Code” means the
Internal Revenue Code of 1986, as amended from time to time.

 

“Disability” means
a condition that, in the judgment of the Board, renders you incapable of performing your duties under this Agreement with or without a
reasonable accommodation.

 

“Person” means
an individual, a corporation, a limited liability company, an association, a partnership, an estate, a trust or any other entity or organization,
other than the Company or any of its Affiliates.

 

7.            Conflicting
Agreements. You hereby represent and warrant that your signing of this Agreement and the performance of your obligations under it
will not breach or be in conflict with any other agreement to which you are a party or are bound, and that you are not now subject to
any covenants against competition or similar covenants or any court orders that could affect the performance of your obligations under
this Agreement. You agree that you will not disclose to or use on behalf of the Company any proprietary information of a third party without
that party’s consent.

 

8.            Withholding.
All payments made by the Company under this Agreement shall be reduced by any tax or other amounts required to be withheld by the Company
under applicable law.

 

    

     

    

 

Mr. James OBrien

October 7, 2019

Page Six

 

9.            Assignment.
Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without
the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement
without your consent to one of its Affiliates or to any Person with whom the Company shall hereafter effect a reorganization, consolidate
with, or merge into or to whom it transfers all or substantially all of its properties or assets. This Agreement shall inure to the benefit
of and be binding upon you and the Company, and each of our respective successors, executors, administrators, heirs and permitted assigns.

 

10.          Severability.
If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction,
then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it
is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid
and enforceable to the fullest extent permitted by law.

 

11.          Miscellaneous.
This Agreement sets forth the entire agreement between you and the Company and replaces all prior and contemporaneous communications,
agreements and understandings, written or oral, with respect to the terms and conditions of your employment. This Agreement may not be
modified or amended, and no breach shall be deemed to be waived, unless agreed to in writing by you and an expressly authorized representative
of the Board. The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content
of any provision of this Agreement. This Agreement may be executed in two counterparts, each of which shall be an original and all of
which together shall constitute one and the same instrument. This Agreement shall be governed and construed in accordance with the laws
of the Commonwealth of Pennsylvania, without regard to the conflict of laws principles thereof.

 

12.          Notices.
Any notices provided for in this Agreement shall be in writing and shall be effective when delivered in person or deposited in the United
States mail, postage prepaid, and addressed to you at your last known address on the books of the Company or, in the case of the Company,
to it at its principal place of business, attention of the Chief Executive Officer, or to such other address as either party may specify
by notice to the other actually received.

 

13.          Section 409A. It
is intended that this Agreement be drafted and administered in compliance with section 409A of the Code, including, but not limited
to, ally future amendments to Code section 409A, and any other Internal Revenue Service or other governmental rulings or
interpretations (together, “Section 409A”) issued pursuant to Section 409A so as not to subject you to payment
of interest or any additional tax under Code section 409A. The parties intend for any payments under this Agreement to either
satisfy the requirements of Section 409A or to be exempt from the application of Section 409A, and this Agreement shall be
construed and interpreted accordingly. Notwithstanding anything in this Agreement to the contrary, all payments to be made upon a
termination of employment under this Agreement will only be made upon a “separation from service” within the meaning of
Section 409A. To the maximum extent permitted under Section 409A, the cash severance benefits payable under this Agreement
are intended to meet the requirements of the short-term deferral exemption under Section 409A and the “separation pay
exception” under Treas. Reg. § 1.409A-1(b)(9)(iii). For purposes of the application of Treas. Reg. §
1.409A-1(b)(4)(or any successor provision), each payment in a series of payments to you will be deemed a separate payment.
Notwithstanding anything herein to the contrary, to the extent any expense, reimbursement or in-kind benefit provided to you
constitutes a “deferral of compensation” within 

 

    

     

    

 

Mr. James OBrien

October 7, 2019

Page Seven

 

the meaning of Section 409A of the Code (i) the amount of
expenses eligible for reimbursement or in-kind benefits provided to you during any calendar year will not affect the amount of
expenses eligible for reimbursement or in-kind benefits provided to you in any other calendar year, (ii) the reimbursements for
expenses for which you are entitled to be reimbursed shall be made on or before the last day of the calendar year following the
calendar year in which the applicable expense is incurred and (iii) the light to payment or reimbursement or in-kind benefits
hereunder may not be liquidated or exchanged for any other benefit.

 

14.          Arbitration.
Any dispute or controversy arising under or in connection with this Agreement or your employment with the Company, other than a claim
for injunctive relief pursuant to the Restrictive Covenants Agreement, shall be settled exclusively by arbitration, conducted before a
single arbitrator in Pittsburgh, Pennsylvania (applying Pennsylvania law) in accordance with the National Rules for the Resolution
of Employment Disputes of the American Arbitration Association then in effect. However, prior to resorting to arbitration, both parties
agree to negotiate in good faith to resolve any such dispute or controversy. The arbiter shall be selected in accordance with the rules of
the American Arbitration Association. The decision of the arbitrator shall be final and binding upon the parties hereto and judgment may
be entered on the arbitrator’s award in any court having jurisdiction. The prevailing party in any such proceeding shall be entitled
to receive from the other party all reasonable attorneys’ fees incurred by such prevailing party and all costs incurred in connection
therewith if and to the extent so awarded by the arbitrator.

 

[remainder of page intentionally left blank]

 

    

     

    

 

Mr. James OBrien

October 7, 2019

Page Eight

 

Please sign this Agreement
in the space provided and return it to me. At the time you sign and return it, and the Company counter-signs it this Agreement will take
effect as a binding agreement between you and the Company on the basis set forth above.

 

	COGNITION THERAPEUTICS, INC.	 	 
	 	 	 
	 	 	 
	 	 	 
	By:	/s/ Kenneth I. Moch	 	By:	/s/ James O’Brien
	Name: 	Kenneth I. Moch	 		James O’Brien
	Title: 	President and Chief Executive Officer	 	 
	 	 	 
	Date signed:          October 7, 2019	 	Date signed:
    October 8, 2019

 

    

     

    

 

EXHIBIT A

 

Restrictive Covenants Agreement

 

    

     

    

 

EMPLOYEE
NON-DISCLOSURE AND

INVENTION ASSIGNMENT AGREEMENT

 

THIS AGREEMENT between Cognition
Therapeutics, Inc. (the “Company”), a Delaware corporation with its principal offices at 2403 Sidney St.,
Suite 261, Pittsburgh, PA 15203 and James M. O’Brien (the “Employee”), an individual residing at the
address set forth on the signature page to this Agreement.

 

Recitals:

 

The parties desire to enter into this Agreement
in connection with the Employee’s employment by the Company.

 

NOW, THEREFORE, in consideration of the employment
of the Employee by the Company and the payment by the Company of compensation to the Employee for services rendered and to be rendered,
and intending to be legally bound hereby, the parties hereto agree as follows:

 

1.            Non-Disclosure
of Confidential Information. The Employee acknowledges that in the course of performing services for the Company, the Employee
may obtain knowledge of the Company’s business plans, products, processes, software, know-how, trade secrets, formulas,
methods, models, prototypes, discoveries, inventions, materials and reagents, improvements, disclosures, customer and supplier
lists, names and positions of employees and/or other proprietary and/or confidential information (collectively, the
 “Confidential Information”). The Employee agrees to keep the Confidential Information secret and confidential and not to
publish, disclose or divulge to any other party, or use for the Employee’s own benefit or to the detriment of the Company,
any Confidential Information without the prior written consent of the Company, whether or not such Confidential Information was
discovered or developed by the Employee. The Employee also agrees not to divulge, publish or use any proprietary and/or
confidential information of others that the Company is obligated to maintain in confidence.

 

2.            Inventions
and Discoveries.

 

(a)           Disclosure. The
Employee shall promptly and fully disclose to the Company, with all necessary detail, all developments, know-how, discoveries,
inventions, improvements, concepts, ideas, formulae, processes and methods (whether copyrightable, patentable or otherwise)
made, received, conceived, acquired or written by the Employee (whether or not at the request or upon the suggestion of the
Company), solely or jointly with others, during the period of the Employee’s engagement by the Company as a consultant
hereunder that (i) relate to any line of business, activity or field of interest or investigation with respect to which the
Employee renders services to the Company or (ii) are otherwise made through the use of the Company’s time, facilities or
materials (all of the foregoing being hereinafter referred to collectively as the “Inventions”).

 

(b)           Assignment
and Transfer. The Employee agrees to assign and transfer to the Company all of the Employee’s right, title and interest in
and to the Inventions, and the Employee further agrees to deliver to the Company any and all drawings, notes, specifications 

 

    

     

    

 

and
data relating to the Inventions,
and to sign, acknowledge and deliver all such further papers, including applications for and assignments of copyrights and patents, and
all renewals thereof, as may be necessary to obtain copyrights and patents for any Inventions in any and all countries and to vest title
thereto in the Company and its successors and assigns and to otherwise protect the Company ’s interests therein.

 

(c)           Power
of Attorney. If the Company is unable, after reasonable effort, to secure the Consultant’s signature on any application
for patent, copyright, trademark or other analogous registration or other documents regarding any legal protection relating to an
Invention, whether because of the Employee’s physical or mental incapacity or for any other reason whatsoever, the Employee
hereby irrevocably designates and appoints each of the President and each Vice President of the Company as the Employee’s
agent and attorney-in-fact, to act for and in the Employee’s behalf and stead to execute and file any such application or
applications or other documents and to do all other lawfully permitted acts to further the prosecution and issuance of patent,
copyright, trademark or other registrations or any other legal protection thereon with respect to an Invention with the same legal
force and effect as if executed by the Employee.

 

(d)           Documentation
and Records. The Employee shall hold in a fiduciary capacity for the benefit of the Company all documentation, disks, programs,
data, records, drawings, manuals, reports, sketches, blueprints, letters, notes, notebooks and all other writings, electronic data,
graphics and tangible information and materials of a secret, confidential or proprietary information nature relating to the Company
or the Company’s business that are in the possession or under the control of the Employee. The Employee agrees that in
connection with any research, development or other services performed for the Company, the Employee will maintain careful, adequate
and contemporaneous written records of all Inventions, which records shall be the property of the Company.

 

3.            Injunctive
Relief. The Employee acknowledges that compliance with this Agreement is necessary to protect the goodwill and other proprietary
interests of the Company. The Employee acknowledges that a breach of this Agreement will result in irreparable and continuing damage
to the Company and its business, for which there will be no adequate remedy at law. The Employee further agrees that in the event of
any breach of this Agreement, the Company and its successors and assigns shall be entitled to injunctive relief and to such
other and further relief and damages as may be proper.

 

4.            No
Right to Employment. It is expressly understood that this Agreement is not intended to define the scope of the Employee’s
employment by the Company or the terms of such employment other than as specifically provided herein. Any such other terms may or
may not be contained in a written agreement. In any event, nothing contained in this Agreement shall be interpreted to create an
employment relationship other than at will.

 

5.            Survival
of Agreement; Binding Nature. It is expressly agreed that the provisions of this Agreement shall survive and apply after the
termination of the Employee’s employment with the Company. This Agreement shall be binding on and inure to the benefit of the
Employee’s executors, administrators or other legal representatives or assigns and on the Company’s successors and
assigns. The Company shall have the right to assign this Agreement without the consent of the Employee.

 

    2

     

    

 

6.            Enforceability.
If any provision of this Agreement shall be invalid or unenforceable, in whole or in part, then such provision shall be deemed to be
modified or restricted to the extent and in the manner necessary to render the same valid and enforceable, or shall be deemed
excised from this Agreement, as the case may require, and this Agreement shall be construed and enforced accordingly to the
maximum extent permitted by law.

 

7.            No
Waiver. No claim or right arising out of a breach or default under this Agreement shall be discharged in whole or in part by a waiver
of that claim or right unless the waiver is in writing and signed by the aggrieved party.

 

8.            Construction.
This Agreement shall be construed and interpreted in accordance with the substantive laws of the Commonwealth of Pennsylvania. This
Agreement supersedes and replaces any existing agreement between the Employee and the Company relating generally to the same subject
matter; and this Agreement may not be modified, in whole or in part, except in writing signed by both of the parties.

 

IN WITNESS WHEREOF, this Agreement has been signed
by the parties as of the date set forth below next to the name of the Employee.

 

	 	 	COGNITION THERAPEUTICS, INC.
	 	 	 	 
	 	 	 	 
	Date:	October 7, 2019	 	By:	/s/ Kenneth I. Moch
	 	 	 
	 	 	Name:        Kenneth I. Moch
	 	 	Title:          President & CEO
	 	 	 
	 	 	 
	Date:	October 8, 2019	 	/s/ James M. O’Brien
	 	 	Employee’s Signature
	 	 	 
	 	 	 
	 	 	James M. O’Brien
	 	 	Name of Employee (please print or type)
	 	 	 
	 	 	 
	 	 	Employee’s Address:
	 	 	20 Hollow Tree Ridge Rd
	 	 	Darien, CT 06828
	 	 	 

 

    3Exhibit 10.1

 

EXECUTION VERSION

 

SUBSCRIPTION AGREEMENT

 

This SUBSCRIPTION AGREEMENT (this “Subscription Agreement”)
is entered into this 16th day of July, 2021, by and among Nexters Inc., a British Virgin Islands business company (the “Issuer”),
Kismet Acquisition One Corp., a British Virgin Islands business company (“Kismet”), Kismet Sponsor Limited, a British
Virgin Islands business company (“Sponsor”), and the undersigned (“Subscriber” or “you”).
Defined terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Business Combination Agreement
(as defined below and as in effect on the date hereof).

 

WHEREAS, this Subscription Agreement is being entered into in connection
with the Business Combination Agreement, dated as of January 31, 2021 (as amended, modified, supplemented or waived from time to time
in accordance with its terms, the “Business Combination Agreement”), among the Issuer, Kismet, Sponsor, Nexters Global
Ltd., a private limited liability company domiciled in Cyprus (the “Company”) and other parties named therein, on the
terms and subject to the conditions set forth therein (the transactions contemplated by the Business Combination Agreement, the “Transactions”);

 

WHEREAS, in connection with the Transactions, Subscriber desires to
subscribe for and purchase ordinary shares (the “Shares”) with no par value in the Issuer (all of the ordinary shares
of the Issuer together, the “Issuer Shares”) set forth on the signature page hereto for a purchase price of $10.00 per
share, for the aggregate purchase price set forth on Subscriber’s signature page hereto (the “Purchase Price”),
and the Issuer desires to issue and sell to Subscriber the Shares in consideration of the payment of the Purchase Price therefor by or
on behalf of Subscriber to the Issuer, all on the terms and conditions set forth herein;

 

WHEREAS, certain other “qualified institutional buyers”
(as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”)) or institutional “accredited
investors” (within the meaning of Rule 501(a)(1), (2), (3) or (7) under the Securities Act) (each, an “Other Subscriber”)
have, severally and not jointly, entered into separate subscription agreements with the Issuer (the “Other Subscription Agreements”),
pursuant to which such Other Subscribers have agreed to purchase Issuer Shares on the Closing Date at the same per share purchase price
as the Subscriber, and the aggregate amount of securities to be sold by the Issuer pursuant to this Subscription Agreement and the Other
Subscription Agreements equals, as of the date hereof, [●] Issuer Shares;

 

WHEREAS, the Issuer publicly filed a registration statement on the
Form F-4 (the “Registration Statement”) with the U.S. Securities Exchange Commission (the “Commission”)
on June 14, 2021 in relation to the Transactions; and

 

WHEREAS, the Sponsor desires to transfer [●] Pubco Private Warrants
(the “Transferring Warrants”) to the undersigned on the terms and conditions set forth herein as consideration by the
undersigned to enter into this Subscription Agreement;

 

NOW, THEREFORE, in consideration of the foregoing and the mutual representations,
warranties and covenants, and subject to the conditions, herein contained, and intending to be legally bound hereby, the parties hereto
hereby agree as follows:

 

		1.	Subscription. Subject to the terms and conditions hereof, at the Closing, Subscriber hereby agrees to subscribe for
and purchase, and the Issuer hereby agrees to issue and sell to Subscriber, upon the payment of the Purchase Price, the Shares (such subscription
and issuance, the “Subscription”).

 

		2.	Warrant Transfer. Subject to the terms and conditions hereof, at the Transfer Closing, Sponsor hereby agrees to transfer,
and the Subscriber hereby agrees to receive, the Transferring Warrants as consideration by the Subscriber to enter into this Subscription
Agreement (such transfer and reception, the “Warrant Transfer”). The Subscriber agrees that neither the Transferring
Warrants nor the Issuer Shares underlying such warrants may be transferred, assigned or sold until 30 days after the completion of a Business
Combination and agrees further that it shall be bound by the transfer restrictions set forth under subsection 2.6.1 of the Private Placement
Warrants Purchase Agreement, dated August 5, 2020, by and among Kismet Acquisition One Corp and Kismet Sponsor Limited (the “Warrant
Agreement”).

 

    

     

    

 

		3.	Representations, Warranties and Agreements.

 

		3.1	Subscriber’s Representations, Warranties and Agreements. To induce the Issuer to issue the Shares to Subscriber and to
induce the Sponsor to transfer the Transferring Warrants to the Subscriber, Subscriber hereby represents and warrants to the Issuer, Kismet
and Sponsor and acknowledges and agrees with the Issuer, Kismet and Sponsor as follows:

 

		a)	Subscriber has been duly formed or incorporated and is validly existing and in good standing under the laws of its jurisdiction of
incorporation or formation, with power and authority to enter into, deliver and perform its obligations under this Subscription Agreement.

 

		b)	This Subscription Agreement has been duly authorized, validly executed and delivered by Subscriber. Assuming that this Subscription
Agreement constitutes the valid and binding agreement of the Issuer, Kismet and Sponsor, this Subscription Agreement is the valid and
binding obligation of Subscriber and is enforceable against Subscriber in accordance with its terms, except as may be limited or otherwise
affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting
the rights of creditors generally, and (ii) principles of equity, whether considered at law or equity.

 

		c)	The execution, delivery and performance by Subscriber of this Subscription Agreement and the consummation of the transactions contemplated
herein do not and will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute
a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of Subscriber
or any of its subsidiaries pursuant to the terms of any indenture, mortgage, deed of trust, loan agreement, lease, license or other agreement
or instrument to which Subscriber or any of its subsidiaries is a party or by which Subscriber or any of its subsidiaries is bound or
to which any of the property or assets of Subscriber or any of its subsidiaries is subject, which would reasonably be expected to have
a material adverse effect on the Subscriber’s ability to enter into and timely perform its obligations under this Subscription Agreement
(a “Subscriber Material Adverse Effect”), (ii) result in any violation of the provisions of the organizational documents
of Subscriber or any of its subsidiaries or (iii) result in any violation of any statute or any judgment, order, rule or regulation
of any court or governmental agency or body, domestic or foreign, having jurisdiction over Subscriber or any of its subsidiaries or any
of their respective properties that would reasonably be expected to have a Subscriber Material Adverse Effect.

 

		d)	Subscriber is either a U.S. investor or non-U.S. investor and:

 

		i)	If a U.S. investor, (i) is a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act (“Rule
144A”)) or an institutional “accredited investor” (within the meaning of Rule 501(a)(1), (2), (3) or (7) under the
Securities Act) satisfying the applicable requirements set forth on Schedule I, (ii) is acquiring the Shares only for its own account
and not for the account of others, or if Subscriber is subscribing for the Shares as a fiduciary or agent for one or more investor accounts,
each owner of such account is a “qualified institutional buyer” or an “accredited investor” (each as defined above)
and Subscriber has full investment discretion with respect to each such account, and the full power and authority to make the acknowledgements,
representations and agreements herein on behalf of each owner of each such account, and (iii) is not acquiring the Shares with a view
to, or for offer or sale in connection with, any distribution thereof in violation of the Securities Act and Subscriber further represents
that Subscriber does not presently have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant
participations in the Shares to such person or to any third person, with respect to any of the Shares. Subscriber has provided the Company
with the requested information on Schedule I following the signature page hereto and the information contained therein is accurate and
complete. Subscriber is not an entity formed for the specific purpose of acquiring the Shares, unless such newly formed entity is an entity
in which all of the equity owners are accredited investors and is an “institutional account” as defined by FINRA Rule 4512(c).
Subscriber acknowledges that the offering meets the exemptions from filing under FINRA Rule 5123(b)(1)(C) or (J).

 

    2

     

    

 

		ii)	If a non-U.S. investor, understands that the sale of the Shares is made pursuant to and in reliance upon Regulation S promulgated
under the Securities Act (“Regulation S”). The Subscriber is not a U.S. Person (as defined in Regulation S), and it
is acquiring the Shares in an offshore transaction in reliance on Regulation S. The Subscriber understands and agrees that Shares sold
pursuant to Regulation S may be subject to restrictions thereunder, including compliance with the distribution compliance period provisions
therein. Subscriber is not an entity formed for the specific purpose of acquiring the Shares, unless such newly formed entity is an entity
in which all of the equity owners are accredited investors and is an “institutional account” as defined by FINRA Rule 4512(c).
Subscriber acknowledges that the offering meets the exemptions from filing under FINRA Rule 5123(b)(1)(C) or (J).

 

		e)	Subscriber (i) if resident in a member state of the European Economic Area, is a “qualified investor” within the
meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published
when securities are offered to the public or admitted to trading on a regulated market (the “EU Prospectus Regulation”),
and (ii) if resident in the United Kingdom, is a “qualified investor” within the meaning of Regulation (EU) 2017/1129 as it
forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the “UK Prospectus Regulation”).

 

		f)	Subscriber understands that the Shares are being offered in a transaction not involving any public offering within the meaning of
the Securities Act, or any “offer of securities to the public” within the meaning of the EU Prospectus Regulation or the UK
Prospectus Regulation, and that the Shares have not been registered under the Securities Act. Subscriber understands that the Shares may
not be resold, transferred, pledged or otherwise disposed of by Subscriber absent an effective registration statement under the Securities
Act, except (i) to the Issuer or a subsidiary thereof, (ii) to non-U.S. persons pursuant to offers and sales that occur solely
outside the United States within the meaning of Regulation S under the Securities Act or (iii) pursuant to another applicable exemption
from the registration requirements of the Securities Act, and in each of cases (i) and (iii), in accordance with any applicable securities
laws of the states and other jurisdictions of the United States, and that any certificates or book entries representing the Shares shall
contain a legend to such effect. Subscriber acknowledges that the Shares will not be eligible for resale pursuant to Rule 144A promulgated
under the Securities Act. Subscriber understands and agrees that the Shares will be subject to the foregoing transfer restrictions and,
as a result, Subscriber may not be able to readily resell the Shares and may be required to bear the financial risk of an investment in
the Shares for an indefinite period of time. Subscriber understands that it has been advised to consult legal counsel prior to making
any offer, resale, pledge or transfer of any of the Shares.

 

		g)	Subscriber understands and agrees that Subscriber is purchasing the Shares directly from the Issuer. Subscriber further acknowledges
that there have been no representations, warranties, covenants or agreements made to Subscriber by the Issuer, Kismet, Sponsor, the Company
or any of their respective affiliates, officers or directors, expressly or by implication, other than those representations, warranties,
covenants and agreements expressly set forth in this Subscription Agreement, and Subscriber is not relying on any representations, warranties
or covenants other than those expressly set forth in this Subscription Agreement. The Subscriber acknowledges that certain information
provided to the Subscriber was based on projections, and such projections were prepared based on assumptions and estimates that are inherently
uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause
actual results to differ materially from those contained in the projections.

 

    3

     

    

 

		h)	Subscriber represents and warrants that its acquisition and holding of the Shares will not constitute or result in a non-exempt prohibited
transaction under Section 406 of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), Section 4975
of the Internal Revenue Code of 1986, as amended (the “Code”), or any applicable similar law.

 

		i)	In making its decision to purchase the Shares, Subscriber represents that it has relied solely upon independent investigation made
by Subscriber and each of the Issuer’s, Kismet’s and Sponsor’s representations, warranties and agreements in Sections 3.2,
3.3 and 3.4 hereof. Without limiting the generality of the foregoing, Subscriber has not relied on any statements or other information
provided by anyone other than the Issuer, Kismet and Sponsor concerning the Issuer, Kismet or Sponsor or the Shares or the offer and sale
of the Shares. Subscriber acknowledges and agrees that Subscriber has received access to and has had an adequate opportunity to review,
such financial and other information as Subscriber deems necessary in order to make an investment decision with respect to the Shares,
including with respect to the Issuer, Kismet, Sponsor, the Company and the Transactions and made its own assessment and is satisfied concerning
the relevant tax and other economic considerations relevant to the Subscriber’s investment in the Shares. Subscriber acknowledges
that it has reviewed the documents made available to the Subscriber by Kismet, Sponsor and the Company. Subscriber represents and agrees
that Subscriber and Subscriber’s professional advisor(s), if any, have had the full opportunity to ask such questions, receive such
answers and obtain such information as Subscriber and such Subscriber’s professional advisor(s), if any, have deemed necessary to
make an investment decision with respect to the Shares. Subscriber acknowledges that the information provided to Subscriber is preliminary
and subject to change.

 

		j)	Subscriber became aware of this offering of the Shares solely by means of direct contact from either the Sponsor, Issuer or Kismet
as a result of a pre-existing substantive relationship (as interpreted in guidance from the Commission under the Securities Act) preceding
the filing of the Registration Statement by the Issuer, with the Issuer, Sponsor, Kismet or their representatives, and the Shares were
offered to Subscriber solely by direct contact between Subscriber and the Sponsor, Issuer or Kismet. Subscriber did not become aware of
this offering of the Shares, nor were the Shares offered to Subscriber, by any other means. Subscriber acknowledges that the Shares (i) were
not offered to it by any form of general solicitation or general advertising, including methods described in section 502(c) of Regulation
D under the Securities Act, or directed selling efforts (within the meaning of Regulation S under the Securities Act) and (ii) are
not being offered to it in a manner involving a public offering under, or in a distribution in violation of, the Securities Act, or any
state securities laws.

 

		k)	Subscriber acknowledges that it is aware that there are substantial risks incident to the purchase and ownership of the Shares. Subscriber
is able to fend for itself in the transactions contemplated herein. Subscriber has such knowledge and experience in financial and business
matters as to be capable of evaluating the merits and risks of an investment in the Shares, and Subscriber has sought such accounting,
legal and tax advice as Subscriber has considered necessary to make an informed investment decision. Subscriber understands and acknowledges
that (A) it (i) is an institutional account as defined in FINRA Rule 4512(c), (ii) is a sophisticated investor, experienced in investing
in private equity transactions and capable of evaluating investment risks independently, both in general and with regard to all transactions
and investment strategies involving a security or securities and (iii) has exercised independent judgment in evaluating its participation
in the purchase of the Shares and (B) the purchase and sale of the Shares hereunder meets the institutional customer exemption under
FINRA Rule 2111(b).

 

		l)	Subscriber represents and acknowledges that Subscriber, alone, or together with any professional advisor(s), has analyzed and considered
the risks of an investment in the Shares and determined that the Shares are a suitable investment for Subscriber and that Subscriber is
able at this time and in the foreseeable future to bear the economic risk of a total loss of Subscriber’s investment in the Issuer.
Subscriber acknowledges specifically that a possibility of total loss exists.

 

    4

     

    

 

		m)	Subscriber understands and agrees that no federal or state agency has passed upon or endorsed the merits of the offering of the Shares
or made any findings or determination as to the fairness of an investment in the Shares.

 

		n)	Subscriber represents and warrants that Subscriber is not (i) a person or entity named on the List of Specially Designated Nationals
and Blocked Persons, the Executive Order 13599 List, the Foreign Sanctions Evaders List, or the Sectoral Sanctions Identification List,
each of which is administered by the U.S. Treasury Department’s Office of Foreign Assets Control (“OFAC”) or
any other Executive Order issued by the President of the United States and administered by OFAC (collectively, “OFAC Lists”),
(ii) owned or controlled by, or acting on behalf of, a person, that is named on an OFAC List; (iii) organized, incorporated, established,
located, resident or born in, or a citizen, national, or the government, including any political subdivision, agency, or instrumentality
thereof, of, Cuba, Iran, North Korea, Syria, Crimea, or any other country or territory embargoed or subject to substantial trade restrictions
by the United States, (iv) a Designated National as defined in the Cuban Assets Control Regulations, 31 C.F.R. Part 515 or (v) a
non-U.S. shell bank or providing banking services indirectly to a non-U.S. shell bank. Subscriber agrees to provide law enforcement agencies,
if requested thereby, such records as required by applicable law; provided, that Subscriber is permitted to do so under applicable
law. Subscriber represents that if it is a financial institution subject to the Bank Secrecy Act (31 U.S.C. Section 5311 et seq.)
(the “BSA”), as amended by the USA PATRIOT Act of 2001 (the “PATRIOT Act”), and its implementing
regulations (collectively, the “BSA/PATRIOT Act”), that Subscriber maintains policies and procedures reasonably designed
to comply with applicable obligations under the BSA/PATRIOT Act. Subscriber also represents that, to the extent required, it maintains
policies and procedures reasonably designed to ensure compliance with OFAC-administered sanctions programs, including for the screening
of its investors (if it has investors) against the OFAC Lists. Subscriber further represents and warrants that, to the extent required,
it maintains policies and procedures reasonably designed to ensure that the funds held by Subscriber and used to purchase the Shares were
legally derived.

 

		o)	If Subscriber is an employee benefit plan that is subject to Title I of ERISA, a plan, an individual retirement account or other arrangement
that is subject to section 4975 of the Code or an employee benefit plan that is a governmental plan (as defined in section 3(32) of ERISA),
a church plan (as defined in section 3(33) of ERISA), a non-U.S. plan (as described in section 4(b)(4) of ERISA) or other plan that is
not subject to the foregoing but may be subject to provisions under any other federal, state, local, non-U.S. or other laws or regulations
that are similar to such provisions of ERISA or the Code, or an entity whose underlying assets are considered to include “plan assets”
of any such plan, account or arrangement (each, a “Plan”) subject to the fiduciary or prohibited transaction provisions
of ERISA or section 4975 of the Code, Subscriber represents and warrants that neither Issuer, nor any of its respective affiliates (the
“Transaction Parties”) has acted as the Plan’s fiduciary, or has been relied on for advice, with respect to its
decision to acquire and hold the Shares, and none of the Transaction Parties shall at any time be relied upon as the Plan’s fiduciary
with respect to any decision to acquire, continue to hold or transfer the Shares.

 

		p)	Except as expressly disclosed in a Schedule 13D or Schedule 13G (or amendments thereto) filed by such Subscriber with the Commission
with respect to the beneficial ownership of Kismet’s ordinary shares prior to the date hereof, Subscriber is not currently (and
at all times through Closing will refrain from being or becoming) a member of a “group” (within the meaning of Section 13(d)(3)
or Section 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or any successor
provision) that beneficially owns more than five percent of Kismet’s Class A ordinary shares and that is acting for the purpose
of acquiring, holding or disposing of equity securities of Kismet (within the meaning of Rule 13d-5(b)(1) under the Exchange Act).

 

    5

     

    

 

		q)	On the date the Purchase Price would be required to be funded to the Issuer pursuant to Section 4.1, Subscriber will have
sufficient immediately available funds to pay the Purchase Price pursuant to Section 4.1.

 

		r)	Subscriber acknowledges that it is not relying upon, and has not relied upon, any statement, representation or warranty made by any
person, firm or corporation (including, without limitation, Kismet, the Company, Sponsor, any of their affiliates or any of its or their
respective control persons, officers, directors or employees), other than the representations and warranties of the Issuer, Kismet and
Sponsor expressly set forth in this Subscription Agreement, in making its investment or decision to invest in the Issuer. Subscriber agrees
that none of any Other Subscriber pursuant to Other Subscription Agreements or any other agreement related to the private placement of
shares of the Issuer’s capital stock (including the controlling persons, officers, directors, partners, agents or employees of any
such Other Subscriber) shall be liable to any Other Subscriber pursuant to this Subscription Agreement or any other agreement related
to the private placement of shares of the Issuer’s capital stock for any action heretofore or hereafter taken or omitted to be taken
by any of them in connection with the purchase of the Shares hereunder.

 

		s)	Subscriber has no binding arrangement in place to sell, transfer or otherwise dispose of any of the Shares.

 

		t)	Subscriber acknowledges that (i) the staff of the SEC issued the Staff Statement on Accounting
and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies on April 12, 2021 (together with any subsequent
guidance, statements or interpretations issued by the SEC or the staff relating thereto or to other accounting matters related to initial
public offering securities or expenses, the “Statement”) and, (ii) Kismet
continues to review the Statement and its implications, including on the financial statements and other information and (iii) any
restatement, revision or other modification of the SEC Documents arising from or relating to Kismet’s review of the Statement shall
be deemed not material for purposes of this Agreement. A copy of the Statement is available to the Subscriber via the SEC’s EDGAR
system.

 

		u)	Subscriber has not executed this Agreement in the Republic of Cyprus.

 

		3.2	Issuer’s Representations, Warranties and Agreements. To induce Subscriber to purchase the Shares and to induce the Sponsor
to transfer the Transferring Warrants to the Subscriber, the Issuer hereby represents and warrants to Subscriber and Sponsor and agrees
with Subscriber as follows:

 

		a)	The Issuer is a business company duly incorporated, validly existing and in good standing under the laws of the British Virgin Islands.
The Issuer has all power (corporate or otherwise) and authority to own, lease and operate its properties and conduct its business as presently
conducted and to enter into, deliver and perform its obligations under this Subscription Agreement.

 

		b)	At Closing, subject to the receipt of the Purchase Price in accordance with the terms of this Subscription Agreement and registration
of the Shares by the Issuer’s transfer agent (the “Transfer Agent”) in the Issuer’s register of members,
the Shares will be validly issued and allotted and fully paid and non-assessable, free and clear of any liens or other restrictions (other
than those arising under applicable securities laws) and will not have been issued in violation of or subject to any preemptive or similar
rights created under the Issuer’s articles of association (as in effect at such time of issuance) or under the BVI Business Companies
Act, 2004 (as amended).

 

		c)	This Subscription Agreement has been duly authorized, executed and delivered by the Issuer and, assuming that this Subscription Agreement
constitutes the valid and binding obligation of Subscriber, is the valid and binding obligation of the Issuer and is enforceable against
it in accordance with its terms, except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium or other laws relating to or affecting the rights of creditors generally and (ii) principles of equity,
whether considered at law or equity.

 

    6

     

    

 

		d)	The execution, delivery and performance of this Subscription Agreement (including compliance by the Issuer with all of the provisions
hereof), issuance and sale of the Shares and the consummation of the certain other transactions contemplated herein will not (i) conflict
with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation
or imposition of any lien, charge or encumbrance upon any of the property or assets of the Issuer pursuant to the terms of any indenture,
mortgage, deed of trust, loan agreement, lease, license or other agreement or instrument to which the Issuer is a party or by which the
Issuer is bound or to which any of the property or assets of the Issuer is subject, which would reasonably be expected to have a material
adverse effect on the ability of the Issuer to enter into and timely perform its obligations under this Subscription Agreement (an “Issuer
Material Adverse Effect”), (ii) result in any violation of the provisions of the organizational documents of the Issuer or (iii) result
in any violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body, domestic or foreign,
having jurisdiction over the Issuer or any of its properties that would reasonably be expected to have an Issuer Material Adverse Effect.

 

		e)	As of the date of this Subscription Agreement, the issued shares of the Issuer consists of 1 fully paid ordinary share with no par
value, and such share is duly authorized and validly issued, and is not subject to preemptive rights or encumbrances. As of the date of
this Subscription Agreement, and immediately prior to Closing, except as set forth above and pursuant to the Other Subscription Agreements,
the Business Combination Agreement and the transactions contemplated thereby, there are no outstanding: (1) shares, equity interests
or voting securities of the Issuer, (2) securities of the Issuer convertible into or exchangeable for shares or other equity interests
or voting securities of the Issuer, or (3) options, warrants or other rights (including preemptive rights) or agreements, arrangements
or commitments of any character, whether or not contingent, of the Issuer to acquire from any individual, entity or other person, and
no obligation of the Issuer to issue, any shares or other equity interests or voting securities of the Issuer (collectively, the “Equity
Interests”) or securities convertible into or exchangeable or exercisable for Equity Interests. As of the date of this Subscription
Agreement and at Closing, there are no stockholder agreements, voting trusts or other agreements or understandings to which the Issuer
is a party or by which it is bound relating to the voting of any securities of the Issuer, other than as contemplated by the Business
Combination Agreement and the transactions contemplated thereby.

 

		f)	Assuming the accuracy of Subscriber’s representations and warranties set forth in Section 3.1 of this Subscription
Agreement, in connection with the offer, sale and delivery of the Shares in the manner contemplated by this Subscription Agreement, no
registration under the Securities Act is required for the offer and sale of the Shares by the Issuer to Subscriber. The Shares (i) were
not offered by any form of general solicitation or general advertising, including methods described in section 502(c) of Regulation D
under the Securities Act, or directed selling efforts (within the meaning of Regulation S under the Securities Act) and (ii) are
not being offered in a manner involving a public offering under, or in a distribution in violation of, the Securities Act, or any state
securities laws.

 

		g)	The Issuer has provided Subscriber an opportunity to ask questions regarding the Issuer and made available to Subscriber all the information
reasonably available to the Issuer that Subscriber has reasonably requested to make an investment decision with respect to the Shares.

 

		h)	The Issuer has made available to Subscriber (including via the Commission’s EDGAR system) a true, correct and complete copy
of each form, report, statement, schedule, prospectus, proxy, registration statement and other documents filed by the Issuer with the
Commission prior to the date of this Subscription Agreement (the “Issuer SEC Documents”) which Issuer SEC Documents,
as of their respective filing dates (or, in the case of the Registration Statement, when declared effective), complied (or, in the case
of the Registration Statement, will comply), in all material respects with the requirements of the Exchange Act applicable to the Issuer
SEC Documents and the rules and regulations of the Commission promulgated thereunder applicable to the Issuer SEC Documents. None of the
Issuer SEC Documents filed under the Exchange Act, contained, when filed or, if amended prior to the date of this Subscription Agreement,
as of the date of such amendment with respect to those disclosures that are amended (or, in the case of the Registration Statement, when
declared effective), any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

    7

     

    

 

		i)	Neither the Issuer, nor any person acting on its behalf has, directly or indirectly, made any offers or sales of any Issuer security
or solicited any offers to buy any security under circumstances that would adversely affect reliance by the Issuer on either Section 4(a)(2)
of the Securities Act or Regulation S under the Securities Act for the exemption from registration for the transactions contemplated hereby
or would require registration of the issuance of the Shares under the Securities Act.

 

		j)	Neither the Issuer, the Company nor Kismet has entered into any subscription agreement, side letter or similar agreement with any
Other Subscriber or any other investor or potential investor in connection with such Other Subscriber’s or investor’s or potential
investor’s direct or indirect investment in the Issuer, the Company or Kismet other than the Business Combination Agreement and
the Other Subscription Agreements. The Other Subscription Agreements have the same Purchase Price as this Subscription Agreement and do
not include terms or conditions that are more advantageous or favorable to any other investor compared to the Subscriber under this Subscription
Agreement, other than with respect to certain settlement arrangements owing to regulatory constraints, and have not been amended in any
material respect following the date of this Subscription Agreement.

 

		k)	Other than in connection with employee stock options, other benefit plan or other forms of employee compensation, none of the Issuer
nor any of its affiliates has offered Issuer Shares or any similar securities during the six months prior to the date hereof to anyone
other than in connection with the Transactions and to Subscriber and other investors in connection with the Other Subscription Agreements.
Other than the foregoing, the Issuer has no intention to offer Issuer Shares or any similar security during the six months from the date
hereof other than in connection with the Transactions, in connection with duly approved acquisitions or in connection with employee stock
options, other benefit plan or other forms of employee compensation.

 

		l)	Except as disclosed in the Issuer SEC Documents and except for such matters as have not had and would not be reasonably likely to
have, individually or in the aggregate, an Issuer Material Adverse Effect, there is no (i) action, suit, claim or other proceeding,
in each case by or before any governmental authority pending, or, to the knowledge of the Issuer, threatened against the Issuer or the
Company, or (ii) judgment, decree, injunction, ruling or order of any governmental entity or arbitrator outstanding against the Issuer
or the Company.

 

		m)	Except as disclosed in the Issuer SEC Documents, neither the Issuer, nor the Company has received any written communication from a
governmental authority that alleges that the Issuer or the Company is not in compliance with or is in default or violation of any applicable
law, except where such non-compliance, default or violation would not be reasonably expected to have, individually or in the aggregate,
an Issuer Material Adverse Effect.

 

		n)	The Issuer is not required to obtain any material consent, waiver, authorization or order of, give any notice to, or make any filing
or registration with, any court or other federal, state, local or other governmental authority, self-regulatory organization or other
person in connection with the issuance of the Shares pursuant to this Subscription Agreement, other than (i) filings with the Commission,
(ii) filings required by applicable state or federal securities laws, (iii) the filings required in accordance with Section 7.20
of this Subscription Agreement; (iv) those required by the Nasdaq Stock Market LLC (“Nasdaq”), and (v) those
required to consummate the Transactions as provided under the Business Combination Agreement.

 

		o)	Upon consummation of the Transactions, the Issuer Shares registered on the Registration Statement will be registered pursuant to Section 12(b)
of the Exchange Act and will be listed for trading on the Nasdaq, and the Shares will be approved for listing on Nasdaq, subject to official
notice of issuance.

 

    8

     

    

 

		p)	Neither the Issuer nor any person acting on its behalf is under any obligation to pay any broker’s fee or finder’s fee
or commission in connection with the sale of the Shares.

 

		q)	The Issuer is not, and immediately after receipt of payment for the Shares of the Issuer will not be, subject to registration as an
“investment company” under the Investment Company Act of 1940, as amended.

 

		r)	Issuer is not (i) a person or entity named on any OFAC Lists; (ii) owned or controlled by, or acting on behalf of, a person, that
is named on an OFAC List; (iii) organized, incorporated, established, located, resident or born in, or a citizen, national, or the government,
including any political subdivision, agency, or instrumentality thereof, of, Cuba, Iran, North Korea, Syria, Crimea, or any other country
or territory embargoed or subject to substantial trade restrictions by the United States, or (iv) a Designated National as defined in
the Cuban Assets Control Regulations, 31 C.F.R. Part 515.

 

		s)	The Issuer has not executed this Agreement in the Republic of Cyprus.

 

		3.3	Kismet’s Representations, Warranties and Agreements. To induce Subscriber to purchase the Shares and to induce the Sponsor
to transfer the Transferring Warrants to the Subscriber, Kismet hereby represents and warrants to Subscriber and Sponsor and agrees with
Subscriber as follows:

 

		a)	Kismet is a business company duly incorporated, validly existing and in good standing under the laws of the British Virgin Islands.
Kismet has all power (corporate or otherwise) and authority to own, lease and operate its properties and conduct its business as presently
conducted and to enter into, deliver and perform its obligations under this Subscription Agreement.

 

		b)	This Subscription Agreement has been duly authorized, executed and delivered by Kismet and, assuming that this Subscription Agreement
constitutes the valid and binding obligation of Subscriber, is the valid and binding obligation of Kismet and is enforceable against it
in accordance with its terms, except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium or other laws relating to or affecting the rights of creditors generally and (ii) principles of equity,
whether considered at law or equity.

 

		c)	The execution, delivery and performance of this Subscription Agreement (including compliance by Kismet with all of the provisions
hereof), issuance and sale of the Shares and the consummation of the certain other transactions contemplated herein will not (i) conflict
with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation
or imposition of any lien, charge or encumbrance upon any of the property or assets of Kismet pursuant to the terms of any indenture,
mortgage, deed of trust, loan agreement, lease, license or other agreement or instrument to which the Issuer is a party or by which Kismet
is bound or to which any of the property or assets of Kismet is subject, which would reasonably be expected to have a material adverse
effect on the ability of Kismet to enter into and timely perform its obligations under this Subscription Agreement (a “Kismet
Material Adverse Effect”), (ii) result in any violation of the provisions of the organizational documents of Kismet or (iii) result
in any violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body, domestic or foreign,
having jurisdiction over Kismet or any of its properties that would reasonably be expected to have a Kismet Material Adverse Effect.

 

		d)	As of the date of this Subscription Agreement, the authorized shares of Kismet consists of an unlimited number of (i) Ordinary shares
of no par value (“Ordinary Shares”), (ii) five classes of preferred shares of no par value (“Preferred Shares”).
As of the date hereof: (i) no Preferred Shares are issued and outstanding; (ii) 31,750,000 Ordinary Shares are issued and outstanding;
and (iii) 19,250,000 warrants, each exercisable to purchase one existing Ordinary Share at $11.50 per share (the “Warrants”)
are outstanding, which Ordinary Shares and Warrants comprise all securities of Kismet issued and outstanding. As of the date of this Subscription
Agreement, and immediately prior to Closing, other than (A) as set forth in the SEC Documents and (B) as contemplated by the Business
Combination Agreement, there are no outstanding (1) shares, equity interests or voting securities of Kismet, (2) securities
of Kismet convertible into or exchangeable for shares or other equity interests or voting securities of Kismet, or (3) options, warrants
or other rights (including preemptive rights) or agreements, arrangements or commitments of any character, whether or not contingent,
of Kismet to acquire from any individual, entity or other person, and no obligation of Kismet to issue, any shares or other equity interests
or voting securities of Kismet (collectively, the “Kismet Equity Interests”) or securities convertible into or exchangeable
or exercisable for Kismet Equity Interests. Except as disclosed in the Kismet SEC Documents, as of the date of this Subscription Agreement
and at Closing, Kismet has no subsidiaries and does not own, directly or indirectly, interests or investments (whether equity or debt)
in any person, whether incorporated or unincorporated. There are no stockholder agreements, voting trusts or other agreements or understandings
to which Kismet a party or by which it is bound relating to the voting of any securities of Kismet, other than (A) as set forth in
the SEC Documents and (B) as contemplated by the Business Combination Agreement.

 

    9

     

    

 

		e)	Kismet has made available to Subscriber (including via the Commission’s EDGAR system) a true and complete copy of each form,
report, statement, schedule, prospectus, proxy, registration statement and other documents filed by Kismet with the Commission prior to
the date of this Subscription Agreement (the “Kismet SEC Documents”) which Kismet SEC Documents, as of their respective
filing dates, complied in all material respects with the requirements of the Exchange Act applicable to the Kismet SEC Documents and the
rules and regulations of the Commission promulgated thereunder applicable to the Kismet SEC Documents. None of the Kismet SEC Documents
filed under the Exchange Act, contained, when filed or, if amended prior to the date of this Subscription Agreement, as of the date of
such amendment with respect to those disclosures that are amended, any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading; provided, that Kismet makes no such representation or warranty with respect to the proxy statement of Kismet to
be filed in connection with the approval of the Business Combination Agreement by the shareholders of Kismet (the “Proxy Statement”)
or any other information relating to the Company or any of its affiliates included in any SEC Document or filed as an exhibit thereto.
Kismet has timely filed each Kismet SEC Document that Kismet was required to file with the Commission since its inception and through
the date hereof, except for its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021. There are no material outstanding
or unresolved comments in comment letters from the Commission staff with respect to any of the SEC Documents (with the exception of the
Registration Statement).

 

		f)	Assuming the accuracy of Subscriber’s representations and warranties set forth in Section  3.1 of this Subscription
Agreement, in connection with the offer, sale and delivery of the Shares in the manner contemplated by this Subscription Agreement, no
registration under the Securities Act is required for the offer and sale of the Shares by the Issuer to Subscriber. Kismet (i) did
not offer the Shares by any form of general solicitation or general advertising, including methods described in section 502(c) of Regulation
D under the Securities Act, or directed selling efforts, and (ii) is not offering the Shares in a manner involving a public offering
under, or in a distribution in violation of, the Securities Act, or any state securities laws.

 

		g)	Except for such matters as have not had and would not be reasonably likely to have, individually or in the aggregate, a Kismet Material
Adverse Effect, there is no (i) action, suit, claim or other proceeding, in each case by or before any governmental authority pending,
or, to the knowledge of Kismet, threatened against Kismet or the Company, or (ii) judgment, decree, injunction, ruling or order of
any governmental entity or arbitrator outstanding against Kismet or the Company.

 

		h)	Neither Kismet, nor to its knowledge, the Company, has received any written communication from a governmental authority that alleges
that Kismet or the Company is not in compliance with or is in default or violation of any applicable law, except where such non-compliance,
default or violation would not be reasonably expected to have, individually or in the aggregate, a Kismet Material Adverse Effect.

 

    10

     

    

 

		i)	Kismet is not required to obtain any material consent, waiver, authorization or order of, give any notice to, or make any filing or
registration with, any court or other federal, state, local or other governmental authority, self-regulatory organization or other person
in connection with the execution, delivery and performance by the Issuer of this Subscription Agreement (including, without limitation,
the issuance of the Shares), other than (i) filings with the Commission, (ii) filings required by applicable state or federal
securities laws, (iii) the filings required in accordance with Section 7.20 of this Subscription Agreement; (iv) those
required by the Nasdaq, and (v) those required to consummate the Transactions, such as antitrust approvals, as provided under the
Business Combination Agreement.

 

		j)	Kismet is not (i) a person or entity named on any OFAC Lists; (ii) owned or controlled by, or acting on behalf of, a person, that
is named on an OFAC List; (iii) organized, incorporated, established, located, resident or born in, or a citizen, national, or the government,
including any political subdivision, agency, or instrumentality thereof, of, Cuba, Iran, North Korea, Syria, Crimea, or any other country
or territory embargoed or subject to substantial trade restrictions by the United States, or (iv) a Designated National as defined in
the Cuban Assets Control Regulations, 31 C.F.R. Part 515.

 

		k)	Neither Kismet nor any person acting on its behalf is under any obligation to pay any broker’s fee or finder’s fee or
commission in connection with the sale of the Shares.

 

		l)	Kismet has not executed this Agreement in the Republic of Cyprus.

 

		3.4	Sponsor’s Representations, Warranties and Agreements. To induce Subscriber to receive the Transferring Warrants, Sponsor
hereby represents and warrants to Subscriber and agrees with Subscriber as follows:

 

		a)	Sponsor is a business company duly incorporated, validly existing and in good standing under the laws of the British Virgin Islands.
Sponsor has all power (corporate or otherwise) and authority to own, lease and operate its properties and conduct its business as presently
conducted and to enter into, deliver and perform its obligations under this Subscription Agreement.

 

		b)	This Subscription Agreement has been duly authorized, executed and delivered by Sponsor and, assuming that this Subscription Agreement
constitutes the valid and binding obligation of Subscriber, is the valid and binding obligation of Sponsor and is enforceable against
it in accordance with its terms, except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium or other laws relating to or affecting the rights of creditors generally and (ii) principles of equity, whether
considered at law or equity.

 

		c)	The execution, delivery and performance of this Subscription Agreement (including compliance by Sponsor with all of the provisions
hereof),transfer of the Transferring Warrants and the consummation of the certain other transactions contemplated herein will not (i)
conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the
creation or imposition of any lien, charge or encumbrance upon any of the property or assets of Sponsor pursuant to the terms of any indenture,
mortgage, deed of trust, loan agreement, lease, license or other agreement or instrument to which the Sponsor is a party or by which Sponsor
is bound or to which any of the property or assets of Sponsor is subject, which would reasonably be expected to have a material adverse
effect on the ability of Sponsor to enter into and timely perform its obligations under this Subscription Agreement (a “Sponsor
Material Adverse Effect”), (ii) result in any violation of the provisions of the organizational documents of Sponsor or (iii)
result in any violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body, domestic
or foreign, having jurisdiction over Sponsor or any of its properties that would reasonably be expected to have a Sponsor Material Adverse
Effect.

 

		d)	As of immediately prior to Closing, Sponsor will be the legal and beneficial owner of [●] Transferring Warrants, all of which
Transferring Warrants will be owned by Sponsor free and clear of any Liens other than those imposed under the Sponsor’s Organizational
Documents, the Warrant Agreement and applicable securities Laws. After giving effect to the Warrant Transfer, the Subscriber shall own
the Transferring Warrants, each exercisable to purchase one existing Ordinary Share at $11.50 per share, free and clear of any Liens other
than those imposed under the Sponsor’s Organizational Documents, the Warrant Agreement and applicable securities Laws.

 

    11

     

    

 

		e)	Sponsor is not (i) a person or entity named on any OFAC Lists; (ii) owned or controlled by, or acting on behalf of, a person, that
is named on an OFAC List; (iii) organized, incorporated, established, located, resident or born in, or a citizen, national, or the government,
including any political subdivision, agency, or instrumentality thereof, of, Cuba, Iran, North Korea, Syria, Crimea, or any other country
or territory embargoed or subject to substantial trade restrictions by the United States, or (iv) a Designated National as defined in
the Cuban Assets Control Regulations, 31 C.F.R. Part 515.

 

		f)	Neither Sponsor nor any person acting on its behalf is under any obligation to pay any broker’s fee or finder’s fee or
commission in connection with the Warrant Transfer.

 

		g)	Sponsor has not executed this Agreement in the Republic of Cyprus.

 

		4.	Settlement Date and Delivery.

 

		4.1	Closing.

 

		a)	The closing of the Subscription contemplated hereby (the “Closing”) shall occur on the Share Acquisition Closing
Date (as such term is defined in the Business Combination Agreement) (the “Closing Date”), and immediately prior to,
the consummation of the Share Acquisition (as such term is defined in the Business Combination Agreement). The Issuer shall require the
Subscriber to subscribe for and purchase the Shares by delivering notice to the Subscriber (the “Closing Notice”),
at least eleven (11) Business Days before the Closing Date, specifying the anticipated Closing Date (the “Expected Date”)
and instructions for wiring the Purchase Price for the Shares to the Issuer. At least three (3) Business Days before the Expected Date,
the Subscriber shall deliver to the Issuer the Purchase Price for the Shares, by wire transfer of United States dollars in immediately
available funds to the account specified by the Issuer in the Closing Notice. At the Closing, upon satisfaction (or, if applicable, waiver)
of the conditions set forth in this Section 4, the Issuer shall deliver to Subscriber the Shares in book entry form, in the
name of Subscriber (or its nominee in accordance with its delivery instructions) or to a custodian designated by Subscriber, as applicable,
and shall provide evidence of the issuance of the Shares as of the Closing Date from the Transfer Agent. In the event the Closing does
not occur within four (4) Business Days of the Expected Date, the Issuer will return the Purchase Price to the Subscriber within
one (1) Business Day thereafter in immediately available funds to the account specified by Subscriber, and any book entries shall
be deemed cancelled. Business Day means any day other than a Saturday, Sunday or a legal holiday on which commercial banking institutions
in New York, New York, London, England, Tortola, the British Virgin Islands, or Nicosia, Cyprus, are authorized to close for business.

 

		b)	The closing of the Warrant Transfer contemplated hereby (the “Transfer Closing”) shall occur on the Closing Date
and immediately after the issuance of the Shares hereunder.

 

		4.2	Conditions to Closing of the Issuer. The Issuer’s obligations to sell and issue the Shares at the Closing are subject
to the fulfillment or (to the extent permitted by applicable law) written waiver, on or prior to the Closing Date, of each of the following
conditions:

 

		a)	Representations and Warranties Correct. The representations and warranties made by Subscriber in Section 3.1 hereof
shall be true and correct in all material respects when made (other than representations and warranties that are qualified as to materiality
or Subscriber Material Adverse Effect, which representations and warranties shall be true and correct in all respects) and shall be true
and correct in all material respects on and as of the Closing Date and, with respect to the representations and warranties set forth in
Section  3.1(s), through the end of the Closing Date (unless they specifically speak as of another date in which case they
shall be true and correct in all material respects as of such date) (other than representations and warranties that are qualified as to
materiality or Subscriber Material Adverse Effect, which representations and warranties shall be true and correct in all respects), with
the same force and effect as if they had been made on and as of said date, but in each case without giving effect to consummation of the
Transactions.

 

    12

     

    

 

		b)	Closing of the Transactions. The Transactions set forth in the Business Combination Agreement shall have been or will be consummated
substantially concurrently with the Closing.

 

		c)	Legality. There shall not be in force any order, judgment, injunction, decree, writ, stipulation, determination or award, in
each case, entered by or with any governmental authority, statute, rule or regulation enjoining or prohibiting the consummation of the
Subscription.

 

		d)	Regulatory. If required by applicable governmental authorities (including, but not limited to, financial services or banking
authorities), Subscriber shall have been found suitable by such authorities.

 

		e)	Performance and Compliance under Subscription Agreement. Subscriber shall have performed, satisfied and complied in all material
respects with all covenants, agreements and conditions required by this Subscription Agreement to be performed, satisfied or complied
with by it at or prior to the Closing.

 

		4.3	Conditions to Closing of Subscriber. Subscriber’s obligation to subscribe for and purchase the Shares at the Closing
is subject to the fulfillment or (to the extent permitted by applicable law) written waiver, on or prior to the Closing Date, of each
of the following conditions:

 

		a)	Representations and Warranties Correct. The representations and warranties made by the Issuer in Section . 3.2
hereof, Kismet in Section 3.3 hereof and Sponsor in Section 3.4 hereof shall be true and correct in all material respects
(other than representations and warranties that are qualified as to materiality, Issuer Material Adverse Effect, Kismet Material Adverse
Effect or Sponsor Material Adverse Effect, which representations and warranties shall be true and correct in all respects) on and as of
the Closing Date (unless they specifically speak as of another date in which case they shall be true and correct in all material respects
as of such date) with the same force and effect as if they had been made on and as of said date, but in each case without giving effect
to consummation of the Transactions.

 

		b)	Closing of the Transactions. All conditions precedent to the Issuer’s, the Company’s, Kismet’s and Sponsor’s
obligations to effect the Transactions set forth in the Business Combination Agreement shall have been satisfied or waived provided that
any such waiver is not materially adverse to the interests of the Subscriber (other than those conditions that, by their nature, may only
be satisfied at the consummation of the Transactions or will be satisfied by the Closing and the consummation of the transactions contemplated
by the Other Subscription Agreements), and the Transactions set forth in the Business Combination Agreement shall have been or will be
consummated substantially concurrently with the Closing.

 

		c)	Legality. There shall not be in force, issued or entered any order, judgment, injunction, decree, writ, stipulation, determination
or award, in each case, entered by or with any governmental authority, statute, rule or regulation enjoining or prohibiting the consummation
of the Subscription and the Warrant Transfer.

 

		d)	Performance and Compliance under Subscription Agreement. The Issuer and Kismet shall have performed, satisfied and complied
in all material respects with all covenants, agreements and conditions required by this Subscription Agreement to be performed, satisfied
or complied with by it at or prior to the Closing, except where the failure of such performance or compliance would not or would not reasonably
be expected to prevent, materially delay, or materially impair the ability of the Issuer and Kismet to consummate the closing of the Transactions.

 

    13

     

    

 

		e)	Listing. The Issuer Shares shall have been approved for listing on the Nasdaq Capital Market LLC, subject to notice of issuance
thereof, and no suspension for the qualification of the Issuer Shares, or initiation or threatening of any proceedings for any such purpose,
shall have occurred.

 

		f)	Business Combination Agreement. The terms of the Business Combination Agreement shall not have been amended, nor rights thereunder
waived, in a manner materially adverse to the interests of the Investor.

 

		5.	Registration Statement.

 

		5.1	The Issuer agrees that, within thirty (30) calendar days after the consummation of the Transactions (the “Filing Date”),
the Issuer will file with the Commission (at the Issuer’s sole cost and expense) a registration statement registering the resale
of the Shares and any other shares of Issuer Shares held by the Subscriber or any of its affiliates (the “F-1 Registration Statement”),
and the Issuer shall use its commercially reasonable efforts to have the F-1 Registration Statement declared effective as soon as practicable
after the filing thereof, but no later than the earlier of (i) the 90th calendar day (if the
Commission notifies the Issuer that it will “review” the F-1 Registration Statement) following the filing thereof and (ii) the
10th Business Day after the date the Issuer is notified (orally or in writing, whichever is earlier)
by the Commission that the F-1 Registration Statement will not be “reviewed” or will not be subject to further review (such
earlier date, the “Effectiveness Date”); provided, however, that the Issuer’s obligations to include such shares
in the Registration Statement are contingent upon Subscriber furnishing in writing to the Issuer such information regarding Subscriber
and its affiliates, the securities of the Issuer held by Subscriber and its affiliates and the intended method of disposition of the Shares
as shall be reasonably requested by the Issuer to effect the registration of the Shares, and Subscriber and such affiliates shall execute
such documents in connection with such registration as the Issuer may reasonably request that are customary of a selling stockholder in
similar situations, including providing that the Issuer shall be entitled to postpone and suspend the effectiveness or use of the F-1
Registration Statement during any customary blackout or similar period or as permitted pursuant to Section 5.4, provided however
that Subscriber shall not in connection with the foregoing be required to execute any lock-up or similar agreement or otherwise be subject
to any contractual restriction on the ability to transfer the Shares. Notwithstanding the foregoing, if the Commission prevents the Issuer
from including any or all of the shares proposed to be registered under the F-1 Registration Statement due to limitations on the use of
Rule 415 of the Securities Act for the resale of the Shares by the applicable stockholders or otherwise, such F-1 Registration Statement
shall register for resale such number of Shares which is equal to the maximum number of Shares as is permitted by the Commission. In such
event, the number of Shares to be registered for each selling stockholder named in the F-1 Registration Statement shall be reduced pro
rata among all such selling stockholders. In no event shall Subscriber be identified as a statutory underwriter in the F-1 Registration
Statement unless requested by the Commission; provided, that if the Commission requests that Subscriber be identified as a statutory
underwriter in the F-1 Registration Statement, Subscriber will have an opportunity to withdraw from the F-1 Registration Statement. For
purposes of clarification, any failure by the Issuer to file the F-1 Registration Statement by the Filing Date or to effect such F-1 Registration
Statement by the Effectiveness Date shall not otherwise relieve the Issuer of its obligations to file or effect the F-1 Registration Statement
as set forth above in this Section 5. As soon as the Issuer is eligible to file the Form F-3, the Issuer may file with the Commission
(at the Issuer’s sole cost and expense) a registration statement on Form F-3 registering the resale of the Shares and any other
shares of the Issuer Shares held by the Subscriber or any of its affiliates.

 

		5.2	In the case of the registration effected by the Issuer pursuant to this Subscription Agreement, the Issuer shall, upon reasonable
request, inform Subscriber as to the status of such registration. At its expense the Issuer shall:

 

		a)	except for such times as the Issuer is permitted hereunder to suspend the use of the prospectus forming part of a F-1 Registration
Statement, use its commercially reasonable efforts to keep such registration, and any qualification, exemption or compliance under state
securities laws which the Issuer determines to obtain, continuously effective with respect to Subscriber, file all reports as required
by the Exchange Act, provide all customary and reasonable cooperation necessary to enable Subscriber to resell the Shares pursuant to
the F-1 Registration Statement, qualify the Shares for listing on the applicable stock exchange on which the Issuer Shares are then listed,
to keep the applicable F-1 Registration Statement or any subsequent shelf registration statement free of any material misstatements or
omissions and update or amend the F-1 Registration Statement as necessary to include the Shares and provide customary notice to holders
of the Shares, until the earlier of the following: (i) Subscriber ceases to hold any Shares, (ii) the date all Shares held by
Subscriber may be sold without restriction under Rule 144, including, without limitation, any volume and manner of sale restrictions and
without the requirement for the Issuer to be in compliance with the current public information required under Rule 144(c)(1) (or Rule
144(i)(2), if applicable), and (iii) three (3) years from the effectiveness of the F-1 Registration Statement;

 

    14

     

    

 

		b)	advise Subscriber within three (3) Business Days:

 

		i)	when a F-1 Registration Statement or any post-effective amendment thereto has become effective;

 

		ii)	of the issuance by the Commission of any stop order suspending the effectiveness of any F-1 Registration Statement or the initiation
of any proceedings for such purpose;

 

		iii)	of the receipt by the Issuer of any notification with respect to the suspension of the qualification of the Shares included therein
for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and

 

		iv)	subject to the provisions in this Subscription Agreement, of the occurrence of any event that requires the making of any changes in
any F-1 Registration Statement or prospectus so that, as of such date, the statements therein are not misleading and do not omit to state
a material fact required to be stated therein or necessary to make the statements therein (in the case of a prospectus, in the light of
the circumstances under which they were made) not misleading.

 

Notwithstanding anything to the contrary set forth herein,
the Issuer shall not, when so advising Subscriber of such events, provide Subscriber with any material, nonpublic information regarding
the Issuer other than to the extent that providing notice to Subscriber of the occurrence of the events listed in (i) through (iv)
above may constitute material, nonpublic information regarding the Issuer;

 

		c)	use its commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of any F-1 Registration
Statement as soon as reasonably practicable;

 

		d)	upon the occurrence of any event contemplated in Section  5.2(b)(iv), except for such times as the Issuer is permitted
hereunder to suspend, and has suspended, the use of a prospectus forming part of a F-1 Registration Statement, the Issuer shall use its
commercially reasonable efforts to as soon as reasonably practicable prepare a post-effective amendment to such F-1 Registration Statement
or a supplement to the related prospectus, or file any other required document so that, as thereafter delivered to purchasers of the Shares
included therein, such prospectus will not include any untrue statement of a material fact or omit to state any material fact necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading;

 

		e)	use its commercially reasonable efforts to cause all Shares to be listed on each securities exchange or market, if any, on which the
Issuer Shares are then listed;

 

    15

     

    

 

		f)	use its commercially reasonable efforts to take all other steps necessary to effect the registration of the Shares contemplated hereby;
and

 

		g)	use its commercially reasonable efforts to file all reports and other materials required to be filed by the Exchange Act so long as
the Issuer remains subject to such requirements and the filing of such reports and other documents is required for the applicable provisions
of Rule 144 to enable the Subscriber to sell the Shares under Rule 144 for so long as the Subscriber holds Shares.

 

		5.3	The Issuer shall use commercially reasonable efforts, if requested by the Subscriber, to (i) cause the removal of any restrictive
legend set forth on the Shares and (ii) issue Shares without any such legend in certificated or book-entry form or by electronic
delivery through The Depository Trust Company, at the Subscriber’s option, within three (3) Business Days of such request,
provided that in each case (a) such Shares are registered for resale under the Securities Act and the Subscriber has sold or proposes
to sell such Shares pursuant to such registration, (b) the Subscriber has sold or transferred, or proposes to sell or transfer, Shares
pursuant to Rule 144 and (c) the Issuer, its counsel or the Transfer Agent have received customary representations and other documentation
from the Subscriber that is reasonably necessary to establish that restrictive legends are no longer required as reasonably requested
by the Issuer, its counsel or the Transfer Agent. With respect to clause (a), while the F-1 Registration Statement is effective, if restrictive
legends are no longer required for such Shares, the Issuer shall, in accordance with the provisions of this Section 5.3 and
within two (2) trading days of any request therefor from the Subscriber accompanied by such customary and reasonably acceptable representations
and other documentation referred to above establishing that restrictive legends are no longer required, deliver to the Transfer Agent
instructions that the Transfer Agent shall make a new, unlegended entry for such book entry Shares.

 

		5.4	Notwithstanding anything to the contrary in this Subscription Agreement, the Issuer shall be entitled to delay or postpone the effectiveness
of the F-1 Registration Statement, and from time to time to require Subscriber not to sell under the F-1 Registration Statement or to
suspend the effectiveness thereof, if the negotiation or consummation of a transaction by the Issuer or its subsidiaries is pending or
an event has occurred, which negotiation, consummation or an event the Issuer’s board of directors reasonably believes, upon the
advice of legal counsel (which may be in-house legal counsel), would require additional disclosure by the Issuer in the F-1 Registration
Statement of material information that the Issuer has a bona fide business purpose for keeping confidential and the non-disclosure of
which in the F-1 Registration Statement would be expected, in the reasonable determination of the Issuer’s board of directors, upon
the advice of legal counsel (which may be in-house legal counsel), to cause the F-1 Registration Statement to fail to comply with applicable
disclosure requirements (each such circumstance, a “Suspension Event”); provided, however, that the Issuer
may not delay or suspend the F-1 Registration Statement on more than two occasions or for more than sixty (60) consecutive calendar
days, or more than one hundred and twenty (120) total calendar days, in each case during any twelve-month period. Upon receipt of
any written notice from the Issuer of the happening of any Suspension Event during the period that the F-1 Registration Statement is effective
or if as a result of a Suspension Event the F-1 Registration Statement or related prospectus contains any untrue statement of a material
fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made (in the case of the prospectus) not misleading, Subscriber agrees that (i) it will immediately discontinue
offers and sales of the Shares under the F-1 Registration Statement (excluding, for the avoidance of doubt, sales conducted pursuant to
Rule 144) until Subscriber receives copies of a supplemental or amended prospectus (which the Issuer agrees to promptly prepare) that
corrects the misstatement(s) or omission(s) referred to above and receives notice that any post-effective amendment has become effective
or unless otherwise notified by the Issuer that it may resume such offers and sales, and (ii) it will maintain the confidentiality
of any information included in such written notice delivered by the Issuer unless (a) otherwise required by law or subpoena or (b) disclosed
to Subscriber’s employees, agents and professional advisors who need to know such information and are obligated to keep it confidential.
If so directed by the Issuer, Subscriber will deliver to the Issuer or, in Subscriber’s sole discretion destroy, all copies of the
prospectus covering the Shares in Subscriber’s possession; provided, however, that this obligation to deliver or destroy
all copies of the prospectus covering the Shares shall not apply (i) to the extent Subscriber is required to retain a copy of such
prospectus (a) in order to comply with applicable legal, regulatory, self-regulatory or professional requirements or (b) in
accordance with a bona fide pre-existing document retention policy or (ii) to copies stored electronically on archival servers as
a result of automatic data back-up.

 

    16

     

    

 

		5.5	Subscriber may deliver written notice (an “Opt-Out Notice”) to the Issuer requesting that Subscriber not receive
notices from the Issuer otherwise required by Section 5.4 ; provided, however, that Subscriber may later revoke any
such Opt-Out Notice in writing. Following receipt of an Opt-Out Notice from Subscriber (unless subsequently revoked), (i) the Issuer shall
not deliver any such notices to Subscriber and Subscriber shall no longer be entitled to the rights associated with any such notice and
(ii) each time prior to Subscriber’s intended use of an effective F-1 Registration Statement, Subscriber will notify the Issuer
in writing at least two (2) Business Days in advance of such intended use, and if a notice of a Suspension Event was previously delivered
(or would have been delivered but for the provisions of this Section 5.5) and the related suspension period remains in effect,
the Issuer will so notify Subscriber, within one (1) Business Day of Subscriber’s notification to the Issuer, by delivering
to Subscriber a copy of such previous notice of Suspension Event, and thereafter will provide Subscriber with the related notice of the
conclusion of such Suspension Event promptly following its availability.

 

		5.6	The Issuer shall, notwithstanding any termination of this Subscription Agreement, indemnify, defend and hold harmless the Subscriber
(to the extent a seller under, or named as a selling stockholder in, the F-1 Registration Statement), the officers, directors, partners,
members, managers, employees, advisers and agents of each of them, and each person who controls the Subscriber (within the meaning of
Section 15 of the Securities Act or Section 20 of the Exchange Act) to the fullest extent permitted by applicable law, from
and against any and all out-of-pocket losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys’
fees) and expenses (collectively, “Losses”), based upon (i) any untrue or alleged untrue statement of a material
fact contained in the F-1 Registration Statement, any prospectus included in the F-1 Registration Statement or any form of prospectus
or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission
to state a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or form
of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading, or (ii) any violation
or alleged violation by the Issuer of the Securities Act, Exchange Act or any state securities law or any rule or regulation thereunder,
in connection with the performance of its obligations under this Section 5, except to the extent, and only to the extent,
that such untrue statements, alleged untrue statements, omissions or alleged omissions are based upon information regarding the Subscriber
furnished in writing to the Issuer by the Subscriber expressly for use therein; provided, however, that the indemnification
contained in this Section 5.6 shall not apply to amounts paid in settlement of any Losses if such settlement is effected without
the consent of the Issuer (which consent shall not be unreasonably withheld, conditioned or delayed). The Issuer shall notify the Subscriber
of the institution, threat or assertion of any proceeding arising from or in connection with the transactions contemplated by this Section 5.6
of which the Issuer is aware. The aggregate liability of the Issuer arising from Sections 5.6 and 5.8 shall not exceed the dollar amount
paid by the Subscriber under this Subscription Agreement.

 

		5.7	The Subscriber shall, severally and not jointly with any Other Subscriber, indemnify and hold harmless the Issuer, its directors,
officers, agents and employees, and each person who controls the Issuer (within the meaning of Section 15 of the Securities Act and
Section 20 of the Exchange Act), to the fullest extent permitted by applicable law, from and against all Losses, as incurred, arising
out of or are based upon any untrue or alleged untrue statement of a material fact contained in any F-1 Registration Statement, any prospectus
included in the F-1 Registration Statement, or any form of prospectus, or in any amendment or supplement thereto or in any preliminary
prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary
to make the statements therein (in the case of any prospectus, or any form of prospectus or supplement thereto, in light of the circumstances
under which they were made) not misleading to the extent, but only to the extent, that such untrue statements or omissions are based upon
information regarding the Subscriber furnished in writing to the Issuer by the Subscriber expressly for use therein; provided,
however, that the indemnification contained in this Section 5.7 shall not apply to amounts paid in settlement of any
Losses if such settlement is effected without the consent of the Subscriber (which consent shall not be unreasonably withheld, conditioned
or delayed). Notwithstanding anything to the contrary herein, in no event shall the liability of the Subscriber be greater in amount than
the dollar amount of the net proceeds received by the Subscriber upon the sale of the Shares giving rise to such indemnification obligation.
The Subscriber shall notify the Issuer promptly of the institution, threat or assertion of any proceeding arising from or in connection
with the transactions contemplated by this Section 5.7 of which the Subscriber is aware. Such indemnity shall remain in full
force and effect regardless of any investigation made by or on behalf of an indemnified party and shall survive the transfer of the Shares
by the Subscriber.

 

    17

     

    

 

		5.8	If the indemnification provided under Section 5.6 or Section 5.7 from the indemnifying party is unavailable
or insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities and expenses referred to
herein, then the indemnifying party, in lieu of indemnifying the indemnified party, shall contribute to the amount paid or payable by
the indemnified party as a result of such losses, claims, damages, liabilities and expenses in such proportion as is appropriate to reflect
the relative fault of the indemnifying party and the indemnified party, as well as any other relevant equitable considerations. The relative
fault of the indemnifying party and indemnified party shall be determined by reference to, among other things, whether any action in question,
including any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact, was made
by, or relates to information supplied by, such indemnifying party or indemnified party, and the indemnifying party’s and indemnified
party’s relative intent, knowledge, access to information and opportunity to correct or prevent such action. The amount paid or
payable by a party as a result of the losses or other liabilities referred to above shall be subject to the limitations set forth in Section 5.6
and Section  5.7 and deemed to include any legal or other fees, charges or expenses reasonably incurred by such party in connection
with any investigation or proceeding. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution pursuant to this Section 5.8 from any person who was not guilty of such
fraudulent misrepresentation. Each indemnifying party’s obligation to make a contribution pursuant to this Section  5.8
shall be individual, not joint and several, and in no event shall the liability of Subscriber hereunder exceed the net proceeds received
by Subscriber upon the sale of the shares giving rise to such indemnification obligation.

 

		5.9	Piggyback Rights. If the Issuer proposes to conduct a registered offering of, or if the Issuer proposes to file a registration
statement under the Securities Act with respect to the registration of, equity securities, or securities or other obligations exercisable
or exchangeable for, or convertible into equity securities, for its own account or for the account of the Significant Shareholders, other
than a registration statement (or any registered offering with respect thereto) (i) filed in connection with any employee stock option
or other benefit plan, including any registration statement on Form S-8, (ii) on Form F-4 or Form S-4 (or similar form that relates to
a transaction subject to Rule 145 under the Securities Act or any successor rule thereto), (iii) for an offering of debt that is convertible
into equity securities of the Issuer (iv) for a dividend reinvestment plan, or (v) for a Block Trade (as defined below), then the Issuer
shall give written notice of such proposed offering to all of the Eligible Subscribers holding Registrable Securities not less than five
(5) business days before the anticipated filing date of the relevant registration statement or, in the case of an underwritten offering
pursuant to a shelf registration, the applicable “red herring” prospectus or prospectus supplement used for marketing such
offering, which notice shall (A) describe the expected amount and type of securities to be included in such offering, the intended method(s)
of distribution, and the name of the proposed managing underwriter or underwriters, if any, in such offering, and (B) offer to all of
the Eligible Subscribers holding Registrable Securities the opportunity to include in such registered offering such number of Registrable
Securities as such Eligible Subscribers may request in writing within three (3) business days after receipt of such written notice (such
registered offering, a “Piggyback Registration”, and the Eligible Subscribers making such request, the “Requesting
Piggyback Holders”). Subject to Section ‎5.9(1), the Issuer shall, in good faith, cause such Registrable Securities
so requested to be included in such Piggyback Registration and, if applicable, shall use its commercially reasonable efforts to cause
the managing underwriter or underwriters of such Piggyback Registration to permit such Registrable Securities to be included therein on
the same terms and conditions as any similar securities of the Issuer included in such registered offering and to permit the sale or other
disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof. The inclusion of any Eligible
Subscriber’s Registrable Securities in a Piggyback Registration shall be subject to such Eligible Subscriber’s agreement to
enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwritten offering.

 

    18

     

    

 

For purposes hereof:

 

“Eligible Subscriber”
means a subscriber (including the Subscriber) that purchased Issuer Shares pursuant to this Subscription Agreement or any Other Subscription
Agreement;

 

“Significant Shareholders”
means Kismet Sponsor Limited, Andrey Fadeev, Boris Gertsovskiv, Everix Investments Limited and any other shareholder of the Issuer holding
in excess of 5% of the total share capital of the Issuer; and

 

“Registrable Security”
shall mean any of the Shares (which, for the avoidance of doubt, shall not include any Issuer Shares purchased except pursuant to a Subscription
Agreement) until the earliest to occur of: (A) a registration statement with respect to the sale of any such Shares shall have become
effective under the Securities Act and such securities shall have been sold, transferred, disposed of or exchanged in accordance with
such registration statement; (B) any such Shares shall have ceased to be outstanding; (C) any such Shares have been sold without
registration pursuant to Rule 144 (or any successor rule promulgated thereafter by the Commission); and (D) any such Shares have been
sold to, or through, a broker, dealer or underwriter in a public distribution or other public securities transaction.

 

		(1)	Reduction of Piggyback Registration. If the managing underwriter or underwriters in an underwritten offering that is to be
a Piggyback Registration, in good faith, advises the Issuer and the Requesting Piggyback Holders pursuant to this Section ‎5.9
in writing that the dollar amount or number of Issuer Shares or other equity securities that the Issuer desires to sell, taken together
with the Issuer Shares or other equity securities, if any, as to which registration or a registered offering has been demanded or requested
by Requesting Piggyback Holders or Significant Shareholders exceeds the maximum dollar amount or maximum number of equity securities that
can be sold in the underwritten offering without adversely affecting the proposed offering price, the timing, the distribution method,
or the probability of success of such offering (such maximum dollar amount or maximum number of such securities, as applicable, the “Maximum
Number of Securities”), then (x) if the registration or registered offering is undertaken for the Issuer’s account, the
Issuer shall include in any such registration or registered offering the Issuer Shares (or other equity securities) in the following order
of priority, without exceeding the Maximum Number of Securities:

 

		(A)	first, all Issuer Shares the Issuer desires to sell;

 

		(B)	second, all Issuer Shares desired to be sold by the Requesting Piggyback Holders and Significant Shareholders desire to sell. As between
the Requesting Piggyback Holders and Significant Shareholders, the remaining Issuer Shares (or other equity securities) shall be allocated
20% for the Eligible Subscribers (as between the Eligible Subscribers pro rata based on the respective number of shares that each such
Eligible Holder have requested to be included), and 80% for the Significant Shareholders (pursuant to any agreement between them with
respect to pro rata cut backs in a registered offering);

 

		(C)	third, all other holders so entitled to participate pursuant to any agreement with respect to such rights; and

 

		(y)	if the registration or registered offering is undertaken pursuant
to request of an Other Subscriber or of a Significant Shareholder the Issuer shall include in any such registration or registered offering
the Issuer Shares (or other equity securities) in the order of priority set out in paragraphs (B) and (C) immediately above, without
exceeding the Maximum Number of Securities.

 

    19

     

    

 

		(2)	Piggyback Registration Withdrawal. Any Requesting Piggyback Holder shall have the right to withdraw from a Piggyback Registration
for any or no reason whatsoever upon written notification to the Issuer and the underwriter or underwriters (if any) of its intention
to withdraw from such Piggyback Registration up to one (1) day prior to the effectiveness of the registration statement filed with the
Commission with respect to such Piggyback Registration or, in the case of a Piggyback Registration pursuant to a shelf registration, the
filing of the applicable “red herring” prospectus or prospectus supplement with respect to such Piggyback Registration used
for marketing such transaction. The Issuer (whether on its own good faith determination or as the result of a request for withdrawal by
persons pursuant to separate written contractual obligations) may withdraw a registration statement filed with the Commission in connection
with a Piggyback Registration at any time prior to the effectiveness of such registration statement. The Issuer shall be responsible for
the Registration Expenses incurred in connection with the Piggyback Registration prior to its withdrawal.

 

		(3)	Subscriber Information. Notwithstanding anything in this Section 5 to the contrary, Subscriber may not participate in
any underwritten offering pursuant to this Section ‎5.9 unless Subscriber (x) agrees to sell Subscriber’s securities
on the basis provided in any underwriting arrangements approved by the Issuer and (y) completes and executes all customary questionnaires,
powers of attorney, indemnities, lock-up agreements, underwriting agreements and other customary documents as may be reasonably required
under the terms of such underwriting arrangements.

 

		5.10	Block Trades. For purposes hereof, “Block Trade” means an offering not involving a public “roadshow,”
commonly known as a “block trade.” Notwithstanding any other provision of this Section 5, at any time and from time
to time when an effective registration statement in respect of the Shares is on file with the Commission, if the Subscriber wishes to
engage in a Block Trade that comprises all of the Registrable Securities held by the Subscriber, then the Subscriber only needs to notify
the Issuer of the Block Trade at least five (5) business days prior to the day such offering is to commence and the Issuer shall use its
commercially reasonable efforts to facilitate such Block Trade by providing access to management and assisting with due diligence, subject
to the provisions of the last paragraph of Section 5.2(b). Section ‎5.9 shall not apply to a Block Trade. The Subscriber
shall have the right to select the placement agents, underwriters or sales agents for such Block Trade (which shall consist of one or
more reputable nationally recognized investment banks).

 

		5.11	Registration Expenses. All Registration Expenses shall be borne by the Issuer. It is acknowledged that Subscriber shall bear,
with respect to Subscriber’s Registrable Securities being sold, all underwriters’ commissions and discounts, brokerage fees
and the expenses of any legal counsel representing Subscriber. For purposes hereof, “Registration Expenses” shall mean
the out-of-pocket expenses of a the relevant registration, including, without limitation, the following: (A) all registration and filing
fees (including fees with respect to filings required to be made with the Financial Industry Regulatory Authority, Inc.) and any national
securities exchange on which the Issuer Shares are then listed; (B) fees and expenses of compliance with securities or blue sky laws (including
reasonable fees and disbursements of outside counsel for the underwriters in connection with blue sky qualifications of Registrable Securities);
(C) printing, messenger, telephone and delivery expenses; (D) reasonable fees and disbursements of counsel for the Issuer; and (E) reasonable
fees and disbursements of all independent registered public accountants of the Issuer incurred in connection with such registration.

 

		5.12	With a view to making available to Subscriber the benefits of Rule 144 promulgated under the Securities Act or any other similar rule
or regulation of the Commission that may at any time permit Subscriber to sell securities of the Issuer to the public without registration,
the Issuer agrees, until the Shares are sold by Subscriber, to:

 

		a)	make and keep public information available, as those terms are understood and defined in Rule 144;

 

		b)	file with the Commission in a timely manner all reports and other documents required of the Issuer under the Securities Act and the
Exchange Act so long as the Issuer remains subject to such requirements and the filing of such reports and other documents is required
for the applicable provisions of Rule 144;

 

    20

     

    

 

		c)	furnish to Subscriber so long as it owns the Shares, as promptly as practicable upon request, (x) a written statement by the Issuer,
if true, that it has complied with the reporting requirements of Rule 144, the Securities Act and the Exchange Act, (y) a copy of the
most recent annual or quarterly report of the Issuer and such other reports and documents so filed by the Issuer with the Commission and
(z) such other information as may be reasonably requested to permit Subscriber to sell such securities pursuant to Rule 144 without registration;

 

		d)	in connection with a sale by Subscriber pursuant to Rule 144, if any legended transfer restrictions are no longer required by the
Securities Act or any applicable state securities laws, upon request of Subscriber, the Issuer shall use its commercially reasonable efforts
to cooperate with Subscriber to have such transfer restrictions removed, including providing authorization to the Transfer agent; and

 

		e)	so long as Subscriber owns the Shares, the Issuer will provide thirty (30) days advance written notice to Subscriber of any distribution
of property other than (i) cash (regardless of currency denomination) or (ii) any interest treated as corporate stock (or any options
or rights to acquire interests treated as corporate stock (including under a rights plan)) or indebtedness for U.S. federal income tax
purposes from the Issuer to the Subscriber (other than (a) stock of, or options in, a “United States real property holding corporation”
within the meaning of section 897 of the Code in which Subscriber would own 50% or more of the equity, by vote or value, (or otherwise
control the entity for purposes of section 892 of the Code) as a result of the distribution, or (b) indebtedness providing for payments
determined by reference to the value of any interest in United States real estate or any proceeds realized from the disposition of United
States real estate). In the event the Subscriber transfers or otherwise disposes of its entire interest the Shares (other than to an affiliate),
the Subscriber shall promptly notify the Issuer and the covenant set forth in this Section 5.12 shall terminate for all purposes.

 

		6.	Termination. This Subscription Agreement shall terminate and be void and of no further force and effect, and all rights
and obligations of the parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon
the earlier to occur of (i) such date and time as the Business Combination Agreement is validly terminated in accordance with its
terms, (ii) upon the mutual written agreement of each of the parties hereto to terminate this Subscription Agreement, (iii) the
Issuer’s notification to Subscriber in writing that it has abandoned its plans to move forward with the Transactions, (iv) if
any of the conditions to Closing set forth in Section 4.2 or Section 4.3 are not satisfied on or prior to the
Closing Date and, as a result thereof, the transactions contemplated by this Subscription Agreement are not consummated at the Closing
or (v) at the election of Subscriber, on or after the date that is 270 days after the date of the execution of the Business Combination
Agreement if the Closing has not occurred on or prior to such date; provided, that nothing herein will relieve any party from liability
for any breach hereof prior to the time of termination, and each party will be entitled to any remedies at law or in equity to recover
losses, liabilities or damages arising from such breach. The Issuer shall promptly notify Subscriber of the termination of the Business
Combination Agreement promptly after the termination of such agreement. Upon termination of this Subscription Agreement pursuant to this
Section 6, after the delivery by the Subscriber of the Purchase Price for the Shares, the Issuer shall promptly (but not later than
one (1) Business Day thereafter) return the Purchase Price to the Subscriber without any deduction for, or on account of, any tax,
withholding, charges or set-off.

 

		7.	Miscellaneous.

 

		7.1	Further Assurances. At the Closing, the parties hereto shall make reasonable efforts to execute and deliver such additional
documents and take such additional actions as the parties reasonably may deem to be practical and necessary in order to consummate the
Subscription as contemplated by this Subscription Agreement.

 

		a)	Subscriber acknowledges that  the Issuer, the Company, Kismet and Sponsor will rely on the acknowledgments, understandings, agreements,
representations and warranties of the Subscriber contained in this Subscription Agreement . Prior to the Closing, Subscriber agrees to
promptly notify the Issuer, Kismet and Sponsor if any of the acknowledgments, understandings, agreements, representations and warranties
made by Subscriber set forth herein are no longer accurate in all material respects.

 

    21

     

    

 

		b)	The Issuer acknowledges that the Subscriber will rely on the acknowledgements, understandings, agreements, representations and warranties
contained in this Subscription Agreement. Prior to the Closing, each of the Issuer, Sponsor and Kismet agrees to promptly notify the Subscriber
if any of the acknowledgements, understandings, agreements, representations and warranties made by Issuer, Sponsor or Kismet, as applicable,
set forth herein are no longer accurate in all material respects.

 

		c)	Kismet acknowledges that the Subscriber will rely on the acknowledgements, understandings, agreements, representations and warranties
contained in this Subscription Agreement. Prior to Closing, Kismet agrees to promptly notify the Subscriber if any of the acknowledgements,
understandings, agreements, representations and warranties made by Kismet set forth herein are no longer accurate in all material aspects.

 

		d)	The Sponsor acknowledges that the Subscriber will rely on the acknowledgements, understandings, agreements, representations and warranties
contained in this Subscription Agreement. Prior to the Closing, the Sponsor agrees to promptly notify the Subscriber if any of the acknowledgements,
understandings, agreements, representations and warranties made by the Sponsor set forth herein are no longer accurate in all material
respects.

 

		e)	Subscriber acknowledges and agrees that other than the Issuer, Kismet and Sponsor, no party to the Business Combination Agreement
nor any Non-Party Affiliate (as defined below), shall have any liability to Subscriber pursuant to, arising out of or relating to this
Subscription Agreement, the negotiation hereof or its subject matter, or the transactions contemplated hereby, including, without limitation,
with respect to any action heretofore or hereafter taken or omitted to be taken by it in connection with the purchase of the Shares or
with respect to any claim (whether in tort, contract or otherwise) for breach of this Subscription Agreement or in respect of any written
or oral representations made or alleged to be made in connection herewith, as expressly provided herein, or for any actual or alleged
inaccuracies, misstatements or omissions with respect to any information or materials of any kind furnished by the Issuer, Kismet, the
Company, Sponsor or any Non-Party Affiliate concerning the Issuer, Kismet, the Company, Sponsor, any of their controlled affiliates, this
Subscription Agreement or the transactions contemplated hereby. For purposes of this Subscription Agreement, “Non-Party Affiliates”
means each former, current or future officer, director, employee, partner, member, manager, direct or indirect equity holder or affiliate
of the Issuer, Kismet, the Company, Sponsor or any of the Issuer’s, Kismet’s, the Company’s or Sponsor’s controlled
affiliates or any family member of the foregoing. The Sponsor’s liability under this Subscription Agreement is limited to the representations
and warranties set out in Section 3.4 and its obligations set out in Section 2. The aggregate liability of the Sponsor
arising from this Subscription Agreement shall not exceed the market value of the Transferring Warrants on the date of the transfer.

 

		f)	Each of the Issuer, Kismet, Subscriber, Sponsor and the Company is irrevocably authorized to produce this Subscription Agreement or
a copy hereof to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters covered
hereby.

 

		g)	The Issuer, Kismet and Sponsor may request from Subscriber such additional information as the Issuer, Kismet and Sponsor may deem
reasonably necessary to evaluate the eligibility of Subscriber to acquire the Shares, and Subscriber shall promptly provide such information
as may be reasonably requested, to the extent readily available and to the extent consistent with its internal policies and procedures;
provided, that, each of the Issuer, Kismet and Sponsor agrees to keep any such information provided by Subscriber confidential.

 

		h)	Except as otherwise expressly stated, each party shall pay all of its own expenses in connection with this Subscription Agreement
and the transactions contemplated herein.

 

    22

     

    

 

		7.2	No Short Sales. Subscriber hereby agrees that neither it, nor any person or entity acting on its behalf or pursuant to any
understanding with the Subscriber, shall, directly or indirectly, engage in any hedging activities or execute any Short Sales (as defined
below) with respect to the securities of Kismet prior to the Closing or the earlier termination of this Subscription Agreement in accordance
with its terms. “Short Sales” shall include, without limitation, all “short sales” as defined in Rule 200
of Regulation SHO under the Exchange Act and all types of direct and indirect stock pledges (other than pledges in the ordinary course
of business as part of prime brokerage arrangements), forward sale contracts, options, puts, calls, swaps and similar arrangements (including
on a total return basis), and sales and other transactions through non-U.S. broker dealers or foreign regulated brokers. Notwithstanding
the foregoing, (a) nothing in this Section  7.2 shall prohibit other entities under common management with Subscriber,
or that share an investment advisor with Subscriber, that have no knowledge of this Subscription Agreement or of Subscriber’s participation
in the Subscription Agreement from entering into any Short Sales and (b) in the case of a Subscriber that is a multi-managed investment
bank or vehicle whereby separate portfolio managers or desks manage separate portions of such Subscriber’s assets, this Section 7.2
shall apply only with respect to the portion of assets managed by the portfolio manager or desk that made the investment decision to purchase
the Shares covered by this Subscription Agreement (the “Investing Portfolio Manager”) and the portfolio managers or
desks who have direct knowledge of the investment decisions made by the Investing Portfolio Manager.

 

		7.3	Additional Information. Kismet, the Issuer and Sponsor may request from the Subscriber such additional information as is necessary
for Kismet the, Issuer or Sponsor, as applicable, to comply with public disclosure requirements of applicable securities laws or any filing
requirements pursuant to the rules of any stock exchange or the Financial Industry Regulatory Authority, and the Subscriber shall provide
such information, subject to compliance with Section 7.19. The Subscriber acknowledges that Kismet, the Issuer or Sponsor may file
a copy of the form of this Subscription Agreement with the Commission as an exhibit to a current or periodic report or a registration
statement of Kismet, the Issuer or Sponsor, as applicable, provided that Subscriber will not be identified in such form.

 

		7.4	Notices. Any notice or communication required or permitted hereunder shall be in writing and either delivered personally, emailed
or sent by overnight mail via a reputable overnight carrier, or sent by certified or registered mail, postage prepaid, and shall be deemed
to be given and received (i) when so delivered personally, (ii) when sent, with no mail undeliverable or other rejection notice,
if sent by email, or (iii) three (3) Business Days after the date of mailing to the address below or to such other address or addresses
as such person may hereafter designate by notice given hereunder (a courtesy copy of any notice sent shall also be sent via email):

 

		a)	if to Subscriber, to such address or addresses set forth on the signature page hereto;

 

		b)	if to the Issuer, to:

 

Nexters Inc. c/o Latham & Watkins (London) LLP

99 Bishopsgate

London, EC2M 3XFUnited Kingdom

Attention: J. David Stewart

Email: j.david.stewart@lw.com

 

		c)	if to Kismet, to:

 

Kismet Acquisition One Corp.

Ritter House, Wickhams Cay II

PO Box 3170, Road Town, Tortola

 

VG1110 British Virgin Islands

Attn: Ivan Tavrin, Chief Executive Officer

Email: tioffice@kismetcg.com

 

    23

     

    

 

with a required copy (which copy shall not constitute notice)
to:

Skadden, Arps, Slate, Meagher & Flom (UK) LLP

40 Bank Street

Canary Wharf

London

E14 5DS

Attention: Pranav Trivedi / Denis Klimentchenko

Email: pranav.trivedi@skadden.com / denis.klimentchenko@skadden.com

 

		d)	if to the Company, to:

 

Nexters Global Ltd.

55, Griva Digeni, 3101

Limassol, Cyprus

Attention: Tatiana Kostrikova

Email: t.kostrikova@nextersglobal.com

 

With a copy (which will not constitute notice) to:

Latham & Watkins LLP

99 Bishopsgate

London, EC2M 3XF

United Kingdom

Attention: J. David Stewart

Email: j.david.stewart@lw.com

 

		e)	if to Sponsor, to:

 

Kismet Sponsor Limited

Ritter House, Wickhams Cay II

PO Box 3170, Road Town, Tortola

 

VG1110 British Virgin Islands

Attn: Natalia Markekova

Email: nmarkelova@kismet-group.com

 

with a required copy (which copy shall not constitute notice)
to:

Skadden, Arps, Slate, Meagher & Flom (UK) LLP

40 Bank Street

Canary Wharf

London

E14 5DS

Attention: Pranav Trivedi / Denis Klimentchenko

Email: pranav.trivedi@skadden.com / denis.klimentchenko@skadden.com

 

		7.5	Entire Agreement. This Subscription Agreement constitutes the entire agreement, and supersedes all other prior agreements,
understandings, representations and warranties, both written and oral, among the parties, with respect to the subject matter hereof, including
any commitment letter entered into relating to the subject matter hereof.

 

		7.6	Modifications and Amendments. This Subscription Agreement may not be amended, modified, supplemented or waived (i) except
by an instrument in writing, signed by the party against whom enforcement of such amendment, modification, supplement or waiver is sought
and (ii) without the prior written consent of the Issuer. In no instance shall any amendment, modification or waiver to the Subscription
Agreement have occurred that confers a benefit to any Other Subscriber unless the Subscriber has been offered the same benefit.

 

    24

     

    

 

		7.7	Assignment. Neither this Subscription Agreement nor any rights, interests or obligations that may accrue to the parties hereunder
(including Subscriber’s rights to purchase the Shares) may be transferred or assigned without the prior written consent of each
of the other parties hereto (other than the Shares acquired hereunder, if any, and then only in accordance with this Subscription Agreement),
other than an assignment to any controlled affiliate of the Subscriber or any fund or account managed by the same investment manager as
the Subscriber or a controlled affiliate thereof, subject to, if such transfer or assignment is prior to the Closing, such transferee
or assignee, as applicable, executing a joinder to this Subscription Agreement or a separate subscription agreement in substantially the
same form as this Subscription Agreement, including with respect to the Purchase Price and other terms and conditions; provided,
however, that, in the case of any such transfer or assignment, the initial party to this Subscription Agreement shall remain bound
by its obligations under this Subscription Agreement.

 

		7.8	Benefit.

 

		a)	Except as otherwise provided herein, this Subscription Agreement shall be binding upon, and inure to the benefit of the parties hereto
and their heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements, representations,
warranties, covenants and acknowledgments contained herein shall be deemed to be made by, and be binding upon, such heirs, executors,
administrators, successors, legal representatives and permitted assigns. Except as provided for in Section 7.1, this Subscription
Agreement shall not confer rights or remedies upon any person other than the parties hereto and their respective successors and assigns.

 

		b)	Each of the Issuer and Subscriber acknowledges and agrees that each representation, warranty, covenant and agreement of the Issuer
and Subscriber hereunder is being made for the benefit of the Company after Closing.

 

		7.9	Governing Law. This Subscription Agreement, and any claim or cause of action hereunder based upon, arising out of or related
to this Subscription Agreement (whether based on law, in equity, in contract, in tort or any other theory) or the negotiation, execution,
performance or enforcement of this Subscription Agreement, shall be governed by and construed in accordance with the laws of the State
of Delaware, without giving effect to the principles of conflicts of law thereof.

 

		7.10	Consent to Jurisdiction; Waiver of Jury Trial. Each of the parties irrevocably consents to the exclusive jurisdiction and venue
of the Court of Chancery of the State of Delaware, provided, that if subject matter jurisdiction over the matter that is the subject
of the legal proceeding is vested exclusively in the United States federal courts, such legal proceeding shall be heard in the United
States District Court for the District of Delaware (together with the Court of Chancery of the State of Delaware, the “Chosen
Courts”), in connection with any matter based upon or arising out of this Subscription Agreement. Each party hereby waives,
and shall not assert as a defense in any legal dispute, that (i) such person is not personally subject to the jurisdiction of the
Chosen Courts for any reason, (ii) such legal proceeding may not be brought or is not maintainable in the Chosen Courts, (iii) such
person’s property is exempt or immune from execution, (iv) such legal proceeding is brought in an inconvenient forum or (v) the
venue of such legal proceeding is improper. Each party hereby consents to service of process in any such proceeding in any manner permitted
by Delaware law, further consents to service of process by nationally recognized overnight courier service guaranteeing overnight delivery,
or by registered or certified mail, return receipt requested, at its address specified pursuant to Section 7.4 and waives
and covenants not to assert or plead any objection which they might otherwise have to such manner of service of process. Notwithstanding
the foregoing in this Section 7.10, a party may commence any action, claim, cause of action or suit in a court other than
the Chosen Courts solely for the purpose of enforcing an order or judgment issued by the Chosen Courts. TO THE EXTENT NOT PROHIBITED BY
APPLICABLE LAW WHICH CANNOT BE WAIVED, EACH OF THE PARTIES WAIVES ANY RIGHT TO TRIAL BY JURY ON ANY CLAIMS OR COUNTERCLAIMS ASSERTED IN
ANY LEGAL DISPUTE RELATING TO THIS SUBSCRIPTION AGREEMENT WHETHER NOW EXISTING OR HEREAFTER ARISING. IF THE SUBJECT MATTER OF ANY SUCH
LEGAL DISPUTE IS ONE IN WHICH THE WAIVER OF JURY TRIAL IS PROHIBITED, NO PARTY SHALL ASSERT IN SUCH LEGAL DISPUTE A NONCOMPULSORY COUNTERCLAIM
ARISING OUT OF OR RELATING TO THIS SUBSCRIPTION AGREEMENT. FURTHERMORE, NO PARTY SHALL SEEK TO CONSOLIDATE ANY SUCH LEGAL DISPUTE WITH
A SEPARATE ACTION OR OTHER LEGAL PROCEEDING IN WHICH A JURY TRIAL CANNOT BE WAIVED.

 

    25

     

    

 

		7.11	Severability. If any provision of this Subscription Agreement shall be invalid, illegal or unenforceable, the validity, legality
or enforceability of the remaining provisions of this Subscription Agreement shall not in any way be affected or impaired thereby and
shall continue in full force and effect.

 

		7.12	No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under
this Subscription Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or
remedy of such party. No single or partial exercise of any right, power or remedy under this Subscription Agreement by a party hereto,
nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or
further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a party hereto shall
not constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly
required under this Subscription Agreement shall entitle the party receiving such notice or demand to any other or further notice or demand
in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further
action in any circumstances without such notice or demand.

 

		7.13	Remedies.

 

		a)	The parties agree that irreparable damage would occur if this Subscription Agreement was not performed or the Closing is not consummated
in accordance with its specific terms or was otherwise breached and that money damages or other legal remedies would not be an adequate
remedy for any such damage. It is accordingly agreed that the parties hereto shall be entitled to equitable relief, including in the form
of an injunction or injunctions, to prevent breaches or threatened breaches of this Subscription Agreement and to enforce specifically
the terms and provisions of this Subscription Agreement in an appropriate court of competent jurisdiction as set forth in Section 7.10,
this being in addition to any other remedy to which any party is entitled at law, in equity, in contract, in tort or otherwise, including
money damages. The right to specific enforcement shall include the right of the Issuer, Sponsor or Kismet to cause Subscriber and the
right of Kismet, Sponsor or the Subscriber to cause the Issuer to cause the transactions contemplated hereby to be consummated on the
terms and subject to the conditions and limitations set forth in this Subscription Agreement. The parties hereto further agree (i) to
waive any requirement for the security or posting of any bond in connection with any such equitable remedy, (ii) not to assert that
a remedy of specific enforcement pursuant to this Section 7.13 is unenforceable, invalid, contrary to applicable law or inequitable
for any reason and (iii) to waive any defenses in any action for specific performance, including the defense that a remedy at law
would be adequate.

 

		b)	The parties acknowledge and agree that this Section 7.13 is an integral part of the transactions contemplated hereby and
without that right, the parties hereto would not have entered into this Subscription Agreement.

 

		7.14	Survival of Representations and Warranties. All representations and warranties made by the parties hereto in this Subscription
Agreement shall survive the Closing. For the avoidance of doubt, if for any reason the Closing does not occur prior to the consummation
of the Transactions, all representations, warranties, covenants and agreements of the parties hereunder shall survive the consummation
of the Transactions and remain in full force and effect.

 

    26

     

    

 

		7.15	Headings and Captions. The headings and captions of the various subdivisions of this Subscription Agreement are for convenience
of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof.

 

		7.16	Counterparts. This Subscription Agreement may be executed in one or more counterparts, all of which when taken together shall
be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to
the other parties, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered
by facsimile transmission or any other form of electronic delivery, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original
thereof.

 

		7.17	Construction. The words “include,” “includes,” and “including” will
be deemed to be followed by “without limitation.” Pronouns in masculine, feminine, and neuter genders will be construed
to include any other gender, and words in the singular form will be construed to include the plural and vice versa, unless the context
otherwise requires. The words “this Subscription Agreement,” “herein,” “hereof,”
“hereby,” “hereunder,” and words of similar import refer to this Subscription Agreement as a whole
and not to any particular subdivision unless expressly so limited. The parties hereto intend that each representation, warranty, and covenant
contained herein will have independent significance. If any party hereto has breached any representation, warranty, or covenant contained
herein in any respect, the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless
of the relative levels of specificity) which such party hereto has not breached will not detract from or mitigate the fact that such party
hereto is in breach of the first representation, warranty, or covenant. All references in this Subscription Agreement to numbers of shares,
per share amounts and purchase prices shall be appropriately adjusted to reflect any stock split, stock dividend, stock combination, recapitalization
or the like occurring after the date hereof.

 

		7.18	Mutual Drafting. Each provision of this Subscription Agreement has been subject to the mutual consultation, negotiation and
agreement of the parties and shall not be construed for or against any party hereto.

 

		7.19	Consent to Disclosure. To the extent required by the federal securities laws or the Commission or any other securities authorities,
any other documents or communications provided by the Issuer, Kismet, Sponsor or the Company to any governmental authority or to securityholders
of the Issuer, Subscriber hereby consents to the publication and disclosure in the Form 8-K filed by Kismet with the Commission in connection
with the Proxy Statement of Subscriber’s identity and beneficial ownership of the Shares and the nature of Subscriber’s commitments,
arrangements and understandings under and relating to this Subscription Agreement, provided that the Issuer, Kismet or Sponsor shall provide
Subscriber (to the extent legally permissible) with prior written notice of such disclosure permitted under this clause. Notwithstanding
anything in this Subscription Agreement to the contrary, the Issuer, the Company, Sponsor and Kismet shall not, without the prior written
consent of Subscriber, publicly disclose the name of Subscriber or any of its advisors or affiliates, or include the name of Subscriber
or any of its affiliates (i) in any press release or (ii) in any filing with the Commission or any regulatory agency or trading market,
without the prior written consent of Subscriber, except to the extent such disclosure is required by law, in which case the Issuer shall
provide Subscriber with prior written notice of such disclosure permitted under this clause and shall reasonably consult with Subscriber
regarding such disclosure.

 

		7.20	Trust Account Waiver. Notwithstanding anything to the contrary set forth herein, Subscriber acknowledges that it has read the
Investment Management Trust Agreement, dated as of August  5, 2020, by and between Kismet and Continental Stock Transfer &
Trust Company, a New York corporation, and understands that Kismet has established the trust account described therein (the “Trust
Account”) for the benefit of Kismet’s public stockholders and that disbursements from the Trust Account are available
only in the limited circumstances set forth therein. Subscriber further acknowledges and agrees that Kismet’s sole assets consist
of the cash proceeds of Kismet’s initial public offering and private placements of its securities, and that substantially all of
these proceeds have been deposited in the Trust Account for the benefit of its public stockholders. Accordingly, Subscriber (on behalf
of itself and its affiliates) hereby waives any past, present or future claim of any kind arising out of this Subscription Agreement against,
and any right to access, the Trust Account, any trustee of the Trust Account and Kismet to collect from the Trust Account any monies that
may be owed to them by Kismet or any of its affiliates for any reason whatsoever, and will not seek recourse against the Trust Account
at any time for any claim of any kind arising out of this Subscription Agreement, including, without limitation, for any knowing and intentional
material breach by any of the parties to this Subscription Agreement of any of its representations or warranties as set forth in this
Subscription Agreement, or such party’s material breach of any of its covenants or other agreements set forth in this Subscription
Agreement, which material breach constitutes, or is a consequence of, a purposeful act or failure to act by such party with the knowledge
that the taking of such act or failure to take such act would cause a material breach of this Subscription Agreement; provided,
however, that nothing in this Section 7.20 shall (i) serve to limit or prohibit Subscriber’s right to pursue
a claim against Kismet for legal relief against assets held outside the Trust Account (so long as such claim would not affect Kismet’s
ability to fulfill its obligation to effectuate any redemption right with respect to any securities of Kismet), for specific performance
or other equitable relief, (ii) serve to limit or prohibit any claims that the Subscriber may have in the future against Kismet’s
assets or funds that are not held in the Trust Account (including any funds that have been released from the Trust Account and any assets
that have been purchased or acquired with any such funds) (so long as such claim would not affect Kismet’s ability to fulfill its
obligation to effectuate any redemption right with respect to any securities of Kismet) or (iii) be deemed to limit Subscriber’s
right, title, interest, or claim to the Trust Account by virtue of Subscriber’s record or beneficial ownership of securities of
Kismet acquired by any means other than pursuant to this Subscription Agreement, including any redemption right with respect to any such
securities of Kismet. This Section 7.20 shall survive the termination of this Subscription Agreement for any reason.

 

    27

     

    

 

		8.	Independent Obligations. The obligations of Subscriber under this Subscription Agreement are several and not joint with
the obligations of any Other Subscriber or any other investor under the Other Subscription Agreements, and Subscriber shall not be responsible
in any way for the performance of the obligations of any Other Subscriber under Other Subscription Agreements or any other investor under
the Other Subscription Agreements. The decision of Subscriber to purchase Shares pursuant to this Subscription Agreement has been made
by Subscriber independently of any Other Subscriber or any other investor and independently of any information, materials, statements
or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition (financial or otherwise)
or prospects of the Company or any of its subsidiaries which may have been made or given by any Other Subscriber or investor or by any
agent or employee of any Other Subscriber or investor, and neither Subscriber nor any of its agents or employees shall have any liability
to any Other Subscriber or investor (or any other person) relating to or arising from any such information, materials, statements or opinions.
Nothing contained herein or in any Other Subscription Agreement, and no action taken by Subscriber or investor pursuant hereto or thereto,
shall be deemed to constitute the Subscriber and other investors as a partnership, an association, a joint venture or any other kind of
entity, or create a presumption that the Subscriber and other investors are in any way acting in concert or as a group with respect to
such obligations or the transactions contemplated by this Subscription Agreement and the Other Subscription Agreements. Subscriber acknowledges
that no Other Subscriber has acted as agent for the Subscriber in connection with making its investment hereunder and no Other Subscriber
will be acting as agent of the Subscriber in connection with monitoring its investment in the Shares or enforcing its rights under this
Subscription Agreement. Subscriber shall be entitled to independently protect and enforce its rights, including without limitation the
rights arising out of this Subscription Agreement, and it shall not be necessary for any Other Subscriber or investor to be joined as
an additional party in any proceeding for such purpose.

 

[Signature Page Follows]

 

    28

     

    

 

IN WITNESS WHEREOF, each of the Issuer and Subscriber has executed
or caused this Subscription Agreement to be executed by its duly authorized representative as of the date first set forth above.

 

	 	ISSUER:
	 	 
	 	NEXTERS INC.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	KISMET:
	 	 
	 	KISMET ACQUISITION ONE CORP.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	SPONSOR:
	 	 
	 	KISMET SPONSOR LIMITED
	 	 
	 	By:	
	 	 	Name:
	 	 	Title:

 

    29

     

    

 

	
    SUBSCRIBER:

     
	 	Signature of Joint Subscriber, if applicable:
	
    Signature of Subscriber:

     
	 	 
	By:	 	 	By:	N/A
	Name:	 	 	Name:	
	Title:	 	 	Title:	 
	Date:	July     , 2021	 	 

 

	
    Name of Subscriber:

     

    ______________________________________________
	 	
    Name of Joint Subscriber, if applicable:

     

    N/A _________________________________________

	Please print. Please indicate name and capacity of

 person signing above)	 	Please print. Please indicate name and capacity of

 person signing above)

 

	Name in which securities are to be registered(if different from the name of Subscriber listed directly above):	 
	
    Email Address: _________________________

    If there are joint investors, please check one: N/A

    ☐
    Joint Tenants with Rights of Survivorship

    ☐
    Tenants-in-Common

    ☐
    Community Property
	 
	Subscriber’s EIN:___________________________	Joint Subscriber’s EIN: N/A  _______________________
	Business Address-Street:	Mailing Address-Street (if different):
	City, State, Zip:  ____________________________	City, State, Zip:  _________________________________
	Attn:  ____________________________________	Attn:  _________________________________________
	Telephone No:  _____________________________	Telephone No:  _________________________________
	Facsimile No.:  ______________________________	Facsimile No.:  __________________________________
	 	 
	Aggregate Number of Shares subscribed for: 	 
	Aggregate Purchase Price:  ______________________	 
	 	 

 

You must pay the Purchase Price by wire transfer of U.S. dollars in
immediately available funds to the account specified by the Issuer in the Closing Notice.

 

    

     

    

 

SCHEDULE I

ELIGIBILITY REPRESENTATIONS APPLICABLE TO U.S. SUBSCRIBER

 

A. QUALIFIED INSTITUTIONAL BUYER STATUS

 

(Please check the applicable subparagraphs):

 

1. ☐
We are a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities
Act”)) (a “QIB”) and have marked and initialed the appropriate box on the following pages indicating the
provision under which we qualify as a QIB.

 

2. ☐
We are subscribing for the Shares as a fiduciary or agent for one or more investor accounts, and each owner of such account is a QIB.

 

*** OR ***

 

B. INSTITUTIONAL ACCREDITED INVESTOR
STATUS (Please check the applicable subparagraphs):

 

1. ☐
We are an institutional “accredited investor” (within the meaning of Rule 501(a) under the Securities Act or an entity in
which all of the equity holders are institutional accredited investors) and have marked and initialed the appropriate box on the following
pages indicating the provision under which we qualify as an institutional “accredited investor.”

 

2. ☐
We are not a natural person.

 

*** AND ***

 

C. AFFILIATE STATUS (Please check the
applicable box)

 

SUBSCRIBER:

 

☐
is:

 

☐
is not:

 

an “affiliate” (as defined in Rule 144 under the Securities
Act) of the Issuer or acting on behalf of an affiliate of the Issuer.

 

This page should be completed by Subscriber

and constitutes a part of the Subscription Agreement.

 

    Schedule I -1

     

    

 

The Subscriber is a “qualified institutional buyer” (within
the meaning of Rule 144A under the Securities Act) if it is an entity that meets any one of the following categories at the time of the
sale of securities to the Subscriber (Please check the applicable subparagraphs):

 

☐
The Subscriber is an entity that, acting for its own account or the accounts of other qualified institutional buyers, in the aggregate
owns and invests on a discretionary basis at least $100 million in securities of issuers that are not affiliated with the Subscriber
and:

 

☐
is an insurance company as defined in section 2(a)(13) of the Securities Act;

 

☐
is an investment company registered under the Investment Company Act of 1940, as amended (the “Investment Company Act”),
or any business development company as defined in section 2(a)(48) of the Investment Company Act;

 

☐
is a Small Business Investment Company licensed by the US Small Business Administration under section 301(c) or (d) of the Small
Business Investment Act of 1958, as amended (“Small Business Investment Act”);

 

☐
is a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political
subdivisions, for the benefit of its employees;

 

☐
is an employee benefit plan within the meaning of Title I of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”);

 

☐
is a trust fund whose trustee is a bank or trust company and whose participants are exclusively (a) plans established and maintained
by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of
its employees, of (b) employee benefit plan within the meaning of Title I of the ERISA, except, in each case, trust funds that include
as participants individual retirement accounts or H.R. 10 plans;

 

☐
is a business development company as defined in section 202(a)(22) of the Investment Advisers Act of 1940, as amended (the “Investment
Advisers Act”);

 

☐
is an organization described in section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”),
corporation (other than a bank as defined in section 3(a)(2) of the Act, a savings and loan association or other institution referenced
in section 3(a)(5)(A) of the Act, or a foreign bank or savings and loan association or equivalent institution), partnership, or Massachusetts
or similar business trust; or

 

☐
is an investment adviser registered under the Investment Advisers Act;

 

☐
The Subscriber is a dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), acting for its own account or the accounts of other qualified institutional buyers, that in the aggregate owns and invests
on a discretionary basis at least $10 million of securities of issuers that are not affiliated with the Subscriber;

 

☐
The Subscriber is a dealer registered pursuant to Section 15 of the Exchange Act acting in a riskless principal transaction on behalf
of a qualified institutional buyer;

 

    Schedule I -2

     

    

 

☐
The Subscriber is an investment company registered under the Investment Company Act, acting for its own account or for the accounts of
other qualified institutional buyers, that is part of a family of investment companies1
which own in the aggregate at least $100 million in securities of issuers, other than issuers that are affiliated with Subscriber
or are part of such family of investment companies;

 

☐
The Subscriber is an entity, all of the equity owners of which are qualified institutional buyers, acting for its own account or the accounts
of other qualified institutional buyers; or

 

☐
The Subscriber is a bank as defined in section 3(a)(2) of the Securities Act, or any savings and loan association or other institution
as defined in section 3(a)(5)(A) of the Securities Act, or any foreign bank or savings and loan association or equivalent institution,
acting for its own account or the accounts of other qualified institutional buyers, that in the aggregate owns and invests on a discretionary
basis at least $100 million in securities of issuers that are not affiliated with the Subscriber and that has an audited net worth
of at least $25 million as demonstrated in its latest annual financial statements, as of a date not more than 16 months preceding
the date of sale of securities in the case of a US bank or savings and loan association, and not more than 18 months preceding the date
of sale of securities for a foreign bank or savings and loan association or equivalent institution.

 

Rule 501(a) under the Securities Act, in relevant part, states that
an institutional “accredited investor” shall mean any person who comes within any of the below listed categories, or who the
issuer reasonably believes comes within any of the below listed categories, at the time of the sale of the securities to that person.
Subscriber has indicated, by marking and initialing the appropriate box(es) below, the provision(s) below which apply to Subscriber and
under which Subscriber accordingly qualifies as an institutional “accredited investor.”

 

☐
Any bank as defined in section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in section
3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity;

 

☐
Any broker or dealer registered pursuant to section 15 of the Exchange Act;

 

☐
Any insurance company as defined in section 2(a)(13) of the Securities Act;

 

☐
Any investment company registered under the Investment Company Act or a business development company as defined in section 2(a) (48)
of the Investment Company Act;

 

☐
Any Small Business Investment Company licensed by the U.S. Small Business Administration under section 301(c) or (d) of the Small
Business Investment Act;

 

☐
Any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political
subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000;

 

☐
Any employee benefit plan within the meaning of Title I of the ERISA, if (i) the investment decision is made by a plan fiduciary,
as defined in section 3(21) of ERISA, which is either a bank, a savings and loan association, an insurance company, or a registered investment
adviser, (ii) the employee benefit plan has total assets in excess of $5,000,000 or, (iii) such plan is a self-directed plan,
with investment decisions made solely by persons that are “accredited investors”;

 

☐
Any private business development company as defined in section 202(a)(22) of the Investment Advisers Act;

 

☐
Any (i) corporation, limited liability company or partnership, (ii) Massachusetts or similar business trust, or (iii) organization
described in section 501(c)(3) of the Internal Revenue Code, in each case that was not formed for the specific purpose of acquiring the
securities offered and that has total assets in excess of $5,000,000; or

 

☐
Any trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase
is directed by a sophisticated person as described in section 230.506(b)(2)(ii) of Regulation D under the Securities Act.

 

 

1
“Family of investment companies” means any two or more investment companies registered under the Investment
Company Act, except for a unit investment trust whose assets consist solely of shares of one or more registered investment companies,
that have the same investment adviser (or, in the case of unit investment trusts, the same depositor); provided, that (a) each
series of a series company (as defined in Rule 1 8f-2 under the Investment Company Act) shall be deemed to be a separate investment company
and (b) investment companies shall be deemed to have the same adviser (or depositor) if their advisers (or depositors) are majority-owned
subsidiaries of the same parent, or if one investment company’s adviser (or depositor) is a majority-owned subsidiary of the other
investment company’s adviser (or depositor).

 

 

Schedule I -3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]